



(51) International Patent Classification:

C12N 15/113 (2010.01) A61P 11/00 (2006.01)
C12N 15/115 (2010.01) C07K 16/28 (2006.01)
A61K 31/4545 (2006.01)

(21) International Application Number:

PCT/US2018/027799

(22) International Filing Date:

16 April 2018 (16.04.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/485,863 14 April 2017 (14.04.2017) US

(71) Applicant: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA [US/US]; Tech Transfer Arizona, 220 W. Sixth Street, 4th Floor, Tucson, AZ 85701 (US).

(72) Inventors: GARCIA, Joe, G.N.; c/o Tech Transfer Arizona, 220 W. Sixth Street, 4th Floor, Tucson, AZ 85701 (US). HECKER, Louise; c/o Tech Transfer Arizona, 220 W. Sixth Street, 4th Floor, Tucson, AZ 85701 (US).

(74) Agent: PABST, Patrea, L. et al.; Pabst Patent Group LLP, 1545 Peachtree Street, N.e., Suite 320, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR TREATING PULMONARY FIBROSIS




FIG. 1A

(57) Abstract: Inhibition of the expression and/or function of nicotinamide phosphoribosyltransferase (NAMPT) can reduce, prevent or reverse the pathophysiological vascular changes associated with the onset and progression of Pulmonary Fibrosis. Compositions and methods to inhibit the expression and function of NAMPT for treating and preventing Pulmonary Fibrosis in a subject in need are provided. The compositions and methods are useful for the modulation of pathophysiological processes that contribute to the development and progression of Pulmonary Fibrosis by reducing lung inflammation, aberrant myofibroblast accumulation and deposition of collagen in fibrotic foci.



COMPOSITIONS AND METHODS FOR TREATING PULMONARY FIBROSIS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 62/485,863 entitled "Methods for treating fibrosis" filed April 14, 2017, the contents of which is incorporated by reference in its entirety.

REFERENCE TO SEQUENCE LISTING

The Sequence Listing submitted as a text file named "UA_17_154_PCT_ST25.txt," created on April 16, 2018, and having a size of 17,398 bytes is hereby incorporated by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

This invention was made with US. government support under grant number 1 IK2 BXOOI477-01AI, awarded by the Veteran's Administration. The US. Government has certain rights in the invention.

FIELD OF THE INVENTION

The field of the invention is generally related to compositions, and methods for reducing morbidity and mortality associated with pulmonary fibrosis.

BACKGROUND OF THE INVENTION

Human fibrotic disorders affect many organ systems including the heart, blood vessels, kidney, liver, and lungs. An estimated 45% of deaths in the U.S. are attributable to disorders that are characterized by varying degrees of fibrosis. The most severe form of lung fibrosis is idiopathic pulmonary fibrosis (IPF), a fatal and relentlessly progressive disorder. IPF is characterized by excessive scar tissue formation and irreversible destruction of the lung parenchyma, resulting in gas-exchange abnormalities and respiratory failure. The disease course of IPF is relentlessly progressive; the median survival rate is less than three years. IPF affects approximately 200,000 people in the U.S. and five million worldwide.

Pulmonary fibrosis can develop from acute or chronic injurious exposures, even after the exposure ceases. Thus, patients who have experienced these inhalational exposures are at a higher risk for developing IPF. Aging is a well-recognized risk factor for IPF (mean age = 66 at the time of diagnosis), leading to a significant healthcare burden amongst the aging population. The prevalence of IPF is 20.2 per 100,000 for men and 13.2 per 100,000 for women. IPF is most prevalent among elderly males, and cigarette smoking is a major risk factor for IPF. Tobacco use has been reported for 20% of the US adult population.

Despite the well-recognized role of oxidative stress in fibrosis and aging, the ability to precisely target key mediators of this process has proved difficult. Given this shift in demographic, it is critical to understand the contribution of aging to the cellular/molecular mechanism(s) leading to the pathogenesis of age-related diseases, such as IPF. A major limitation to identification of effective treatments for IPF has been the failure of pre-clinical animal models to reliably reflect human IPF, and to predict efficacy of therapeutic agents in clinical trials. One important reason for this failure is that fibrosis spontaneously resolves in the conventional model of fibrosis in young mice. In resolving fibrosis, lung myofibroblasts (the key 'scar tissue generating' cell) undergo apoptosis to promote healing. In contrast, myofibroblasts from aged mice with non-resolving fibrosis acquire a senescent and apoptosis-resistant phenotype, mediated in part by persistent expression of NADPH-oxidase-4 (Nox4). Similarly, lung myofibroblasts from IPF patients exhibit senescence and apoptosis-resistance, associated with elevated Nox4 expression. However, the mechanisms that drive persistence of Nox4 and apoptosis-resistance of myofibroblasts in the context of aging/IPF remain unknown.

Although two drugs have recently gained FDA-approval for IPF, no drug treatment has been shown to definitively improve quality of life for IPF patients and they have only been shown to delay death by six months. The current drugs only moderately slow the progression of lung decline. There are no available therapies which can 'reverse' fibrosis. Existing treatment

interventions are largely preventative (dosing before or at the time of injury), rather than curative. Clearly, improved therapies for the treatment of IPF and other fibrotic diseases are needed in order to improve the patient experience and outcomes.

Therefore, it is an object of the invention to provide compositions and methods of use thereof for reducing and reversing the pathophysiological processes associated with the onset and progression of pulmonary fibrosis in a subject.

It is also an object of the invention to provide compositions, devices, grafts, and methods of use thereof to reduce or prevent inappropriate or deleterious fibrosis in a subject having idiopathic pulmonary fibrosis.

It is a further object of the invention to provide dosage formulations of compositions effective to treat one or more symptoms of pulmonary fibrosis in a subject.

SUMMARY OF THE INVENTION

It has been established that inhibition of the expression and function of nicotinamide phosphoribosyltransferase (“NAMPT”) reduces or prevents pathophysiological processes that lead to the onset and progression of Pulmonary Fibrosis (PF) in humans. Dosage formulations including one or more NAMPT inhibitors in an amount effective to reduce or prevent the progression of PF in a human are described.

Pharmaceutical compositions to reduce or prevent the progression of PF in a subject in need thereof including one or more inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) enzymatic activity, or one or more inhibitors of NAMPT as a ligand for an inflammatory receptor or one or more inhibitors of the NAMPT receptor (TLR4), or combinations thereof, and a pharmaceutically acceptable excipient for systemic administration are provided. Inhibitors of NAMPT enzymatic activity, inhibitors of NAMPT as a ligand, or inhibitors of the NAMPT receptor include antibodies, antibody fragments, and proteins having the binding specificity of an antibody. In some embodiments, the inhibitor is an F(Ab)

fragment of an antibody, or a divalent F(Ab)₂' fragment of an antibody.

The compositions are effective to reduce or prevent one or more physiological processes associated with the pathology of PF in a subject relative to a control subject. For example, in one embodiment, the compositions are effective to reduce or prevent one or more of the cellular activities associated with PF, including myofibroblast accumulation, excessive extracellular matrix deposition, including collagen and fibronectin deposition in a subject relative to a control subject. Dosage formulations for systemically delivering one or more small molecule inhibitors of NAMPT, or one or more inhibitors of a NAMPT receptor, TLR4, or combinations thereof, in an amount between 10 micrograms to 3.5 mg small molecule (defined as having a molecular weight of 2,000 Daltons, more preferably less than 1,000 Daltons) /kg body weight of a human or between 10 and 400 mg antibody or antibody fragment/kg human body weight are also provided. Dosage forms including one or more inhibitors of NAMPT in an amount for administration by intravenous infusion of between about 10 mg and about 200 mg, inclusive, are provided. In some embodiments, the inhibitor of NAMPT is an antibody or fragment thereof in an amount for administration by infusion of between about 10 mg and about 400 mg, inclusive. In some embodiments, an inhibitor of NAMPT is a F(Ab)₂' fragment in an amount for administration by infusion of between about 10 mg and about 200 mg, inclusive. Small molecules are preferably administered orally once a week and antibody and antibody fragments are preferably administered intravenously once a month for a period of time.

Methods including administering anti-NAMPT antibodies, antibody fragments thereof, or proteins having the binding specificity thereof to a subject by infusion in an amount between 10mg and 400mg are provided. In some embodiments, the infusion is carried out over the course of one hour. The administration can be repeated, preferably once per month.

An exemplary receptor of NAMPT is human Toll-Like Receptor 4 (TLR4). Therefore, exemplary compositions of inhibitors of NAMPT or NAMPT receptors include antibodies, antibody fragments, or proteins having

the binding specificity of antibodies that bind NAMPT or TLR4 and prevent or reduce interaction between NAMPT and TLR4. In some embodiments the anti-NAMPT antibody, or fragment thereof, or protein having the binding affinity thereof binds to an epitope on the NAMPT protein comprising one or more residues selected from the group consisting of Glu445, Gly446, Lys447, Gly448, Asp449, Leu450, Glu451, Glu452, Tyr453, Gly454, His455, Asp456 and Leu457. In other embodiments, the inhibitor of NAMPT binds to the NAMPT molecule to prevent or reduce the homo-dimerization of NAMPT. In other embodiments, the inhibitor of NAMPT binds to the TLR4 receptor to prevent receptor activation by NAMPT.

Inhibitors of NAMPT, inhibitors of NAMPT ligands, or combinations thereof in the form of a functional nucleic acid are also provided. Exemplary functional nucleic acids include antisense molecule, siRNA, miRNA, aptamers, ribozymes, triplex forming molecules, RNAi, and external guide sequences. In some embodiments, one or more functional nucleic acids are expressed from an expression vector.

Inhibitors of NAMPT expression or function, NAMPT receptor ligation, or inhibitors of the NAMPT receptor, TLR4, or combinations thereof, in the form of a small molecule are also provided. Exemplary small molecule inhibitors include FK-866, MS-1-82, Rari049, and A1-pii135. Dosage formulations including one or more small molecule inhibitors of NAMPT enzymatic function, NAMPT receptor ligation, or inhibitors of the NAMPT receptor, TLR4, in an amount for administration of between about 10 µg/kg and about 3.5 mg/kg body weight of the recipient, inclusive, are provided. In an exemplary embodiment, the small molecule inhibitor is Rari049 in an amount of about 2.5 mg/kg body weight of the recipient.

The compositions can also include a delivery vehicle, most typically an aqueous solution such as sterile saline. Other exemplary delivery vehicles include nanoparticles, microparticles, micelles, emulsions, synthetic lipoprotein particles, liposomes, carbon nanotubes, gels, or coatings. The composition can also include one or more additional therapeutic agents. Exemplary additional therapeutic agents include vasoactive compounds, anti-

neointima agents, chemotherapeutic agents, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, immune-suppressants, cytokines, chemokines, and growth factors.

Methods including administering anti-NAMPT antibodies, antibody fragments thereof, or NAMPT inhibitor proteins having the binding specificity thereof to a subject by infusion in an amount between 1mg and 400mg, more preferably between 20mg and 200mg, are provided. The methods reduce or prevent lung inflammation and tissue remodeling in a subject relative to an untreated control subject. In some embodiments, the infusion is carried out over the course of one hour. The administration can be repeated, for example, once per hour, once per day, once per week, once per month, or less frequently. Small molecules are preferably administered orally once a week and antibody and antibody fragments are preferably administered intravenously once a month for a period of time. The methods can administer combinations of NAMPT inhibitors and one or more drugs to the subject.

The methods reduce or prevent one or more of the symptoms of PF in a subject at risk of having PF, or diagnosed with PF. The methods reduce or prevent myofibroblast accumulation in a subject relative to an untreated control subject. The methods can administer combinations of NAMPT inhibitors and one or more vasoactive drugs to the subject.

The methods can reduce or prevent the onset or development of PF, or one or more symptoms of PF in a subject in need thereof. Symptoms of PF that can be reduced, prevented or otherwise managed include dyspnea, fatigue, angina pectoris (chest pain), syncope, edema (swelling/redness), right heart failure, reduced oral intake, dizziness, tachycardia, and palpitation.

The methods can reduce or prevent the onset or development of acute or chronic PF, and/or treat, prevent or manage one or more of the symptoms of acute or chronic PF in the subject relative to an untreated control subject. Acute PF may occur in the intensive care setting.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1C show that aged mice demonstrate lack of resolution to bleomycin-induced lung injury compared to young mice.

Figure 2 shows that fibroblasts isolated from young and aged mice demonstrate p16 induction in response to injury that is transient in young mice, while sustained in aged mice with persistent fibrosis. Fibroblasts isolated from injured lungs of aged mice demonstrate higher levels of senescence-associated β -galactosidase (β gal) activity, a marker of senescence, as compared to young cohorts by cellular staining for β gal. These results demonstrate that non-resolving fibrosis in aged mice is associated with persistence of senescent myofibroblasts.

Figure 3 shows ROS generation in fibroblasts from young and aged mice at the corresponding time points (control, 3w, 2m) evaluated.

Figures 4A and 4B show that lung tissue sections from aged mice post-lung injury show lower levels of apoptosis (TUNEL + cells) in fibrotic regions in comparison to young mice. Fibroblast cells isolated from aged mice demonstrate apoptosis resistance with fewer apoptotic cells with resistance to the apoptosis-inducing agent, staurosporine (**Fig. 4A**). Consistent with the acquisition of an anti-apoptotic phenotype, lungs from aged mice demonstrate elevated levels of Bcl-2 (**Fig. 4B**).

Figure 5 shows heterozygous NAMPT mice *Nampt*^{+/-} are protected from bleomycin-induced lung injury and lung fibrosis reflected by soluble collagen in whole lungs (compared to WT mice 3w post-injury). In response to injury, *Nampt*^{+/-} mice demonstrated increased survival compared to WT mice (80%, n = 8/10 vs. 50%, n = 5/10). These studies demonstrate proof-of-concept that *in vivo* targeting of *Nampt* leads to protection from lung fibrosis.

Figure 6 shows that *iNampt* is aberrantly regulated in aging mice and humans with IPF. *iNampt* is upregulated in representative fibroblasts from senescent and IPF lung fibroblasts. *iNampt* mRNA levels in fibroblasts isolated from advanced vs. early stage IPF patients show increasing *NAMPT* expression with increasing severity (**Fig. 6**).

Figure 7 shows persistent gene expression of *Nampt* (RT-PCR) is associated with non-resolving fibrosis in aging mice evaluated in lung tissue 2m post-injury injury compared to resolving fibrosis in young mice. The 2m post-injury time point represents a point where fibrosis is actively resolving in young mice, whereas aged mice are not.

Figure 8A shows that eNampt increases gene expression of pathways related to fibrosis. Mice were injected intratracheally with 60µg of recombinant Nampt and lung tissue was harvested 4.5h post-administration. RNA was extracted from the lungs and 3 microarray analysis was performed (Affymetrix Mouse430_2). 630 pathways for altered gene expression were assessed. Significant enrichment in several pathways associated with lung fibrosis was identified. Importantly, in response to systemic eNampt, "Lung fibrosis" was among the most significantly altered pathways, 10th most altered out of 640 pathways assessed. **Fig 8B** is a horizontal bar graph showing genome-wide transcriptomic profiling of NAMPT silenced-lung endothelial cells and pathway analysis identifying differentially-regulated pathways. These results support a role for eNampt in mediating fibrotic responses to lung injury.

Figures 9A and 9B show eNampt mediates pro-fibrotic myofibroblast phenotypes. Fibroblasts were dose-dependently treated with exogenous eNampt resulting in increased expression of α SMA, Nox4, iNampt, and GAPDH by western blotting. These results show that eNampt mediates fibroblast-to-myofibroblast differentiation. eNampt led to the induction of oxidant signaling, as demonstrated by dose-dependent increases in Nox4 expression and ROS generation (**Fig. 9A**), and fibroblast senescence (**Fig. 9B**). These studies demonstrate Nampt mediating pro-fibrotic lung myofibroblast phenotypes.

Figure 10 shows that pro-fibrotic effect of eNampt requires TLR4 signaling. eNampt mediates innate immunity and transduces pro-survival signals via its known receptor, TLR4. Lung fibroblasts treated with or without a TLR4 antagonist, a competitive inhibitor of TLR4 (RS-LPS,

Invitrogen), followed by treatment with/without exogenous eNampt (50 ng/ml, 48h) showed that TLR4 blockade prevented eNampt-TLR4 mediated myofibroblast differentiation, inhibited Nox4 induction as determined by Western blot, and led to decreased ROS generation in a dose-dependent manner.

Figures 11A and 11B show that Nampt contributes to mouse and human IPF fibroblasts resistance to apoptosis. Staurosporine (300nM, 8h)-induced expression of apoptotic markers, cleaved caspase 3 and PARP (**Fig 11A**) was increased in lung fibroblasts isolated from Nampt^{+/-} compared with WT mice. **Figure 11B** demonstrates that iNampt enzymatic activity is required for iNAMPT- mediated resistance to staurosporine -induced apoptosis in lung myofibroblasts (which express high levels of iNampt) as IPF fibroblasts pre-treated with FK-866, showed restored apoptosis.

Figures 12A-E show chemical structure of the NAMPT inhibitor, FK-866 (**Fig 12A**) which is divided into three regions (**Fig 12B**) and varied by replacing with N-heterocycles to generate novel FK866 analogs: MS-1-82(**Fig 12C**), Rari049(**Fig 12D**), Alpii135(**Fig 12E**)

Figure 13 is a bar graph showing normalized NAMPT activity in the present of FK866 and FK analogues MS-1-82, Rari049, Alpii135 at 0.1, 1, and 10 μ M concentrations;

Figure 14 is a bar graph showing the role of Nampt enzymatic activity in H₂O₂-induced apoptosis defined by the TUNEL assay. The NAMPT enzymatic inhibitor, FK-866, blocks H₂O₂-induced apoptosis

Figure 15 is a bar graph showing increased lung endothelial cell NAMPT promoter activity in response to IPF-relevant stimuli. Human lung EC, transfected with a NAMPT luciferase promoter in response to VEGF (100 ng/ml) or TGF β 1 (2 ng/ml) after exposure for 4 hr and 24 hr show increased luciferase activity.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

The term “dosing” or “dosage”, refers to the administration of a substance (*e.g.*, an anti-NAMPT antibody) to achieve a therapeutic objective (*e.g.*, the treatment of a NAMPT-associated disorder).

The term “pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents.

The term “inhibit” or other forms of the word such as “inhibiting” or “inhibition” means to hinder or restrain a particular characteristic. It is understood that this is typically in relation to some standard or expected value, *i.e.*, it is relative, but that it is not always necessary for the standard or relative value to be referred to. For example, “inhibits” means hindering, interfering with or restraining the activity of the gene relative to a standard or a control. “Inhibits” can also mean to hinder or restrain the synthesis, expression or function of the protein relative to a standard or control.

“Treatment” or “treating” means to administer a composition to a subject or a system with an undesired condition (*e.g.*, hypertension or a cardiovascular disorder). The condition can include a disease. “Prevention” or “preventing” means to administer a composition to a subject or a system at risk for the condition. The condition can be a predisposition to a disease. The effect of the administration of the composition to the subject (either treating and/or preventing) can be, but is not limited to, the cessation of a particular symptom of a condition, a reduction or prevention of the symptoms of a condition, a reduction in the severity of the condition, the complete ablation of the condition, a stabilization or delay of the development or progression of a particular event or characteristic, or minimization of the chances that a particular event or characteristic will occur.

The term “binding” refers to the interaction between a corresponding pair of molecules or portions thereof that exhibit mutual affinity or binding

capacity, typically due to specific or non-specific binding or interaction, including, but not limited to, biochemical, physiological, and/or chemical interactions. "Binding partner" or "ligand" refers to a molecule that can undergo specific binding with a particular molecule. "Biological binding" defines a type of interaction that occurs between pairs of molecules including proteins, peptides, nucleic acids, glycoproteins, carbohydrates, or endogenous small molecules. "Specific binding" refers to molecules, such as polynucleotides, that are able to bind to or recognize a binding partner (or a limited number of binding partners) to a substantially higher degree than to other, similar biological entities.

The term "antibody" refers to natural or synthetic antibodies that bind a target antigen. The term includes polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term "antibodies" are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules that bind the target antigen. Thus, the term "antibody" encompasses a molecule having at least one variable region from a light chain immunoglobulin molecule and at least one variable region from a heavy chain molecule that in combination form a specific binding site for the target antigen. The antibody can be a IgG antibody, for example, the antibody can be a IgG1, IgG2, IgG3, or IgG4 antibody.

An "antibody fragment" or "antigen binding fragment" of an antibody is defined as at least a portion of the variable region of the immunoglobulin molecule that binds to its target, i.e., the antigen-binding region. An antibody can be in the form of an antigen binding antibody fragment including a Fab fragment, F(ab')₂ fragment, a single chain variable region, and the like.

Fragments of intact molecules can be generated using methods well known in the art and include enzymatic digestion and recombinant means.

As used herein, the term "single chain Fv" or "scFv" as used herein means a single chain variable fragment that includes a light chain variable region (V_L) and a heavy chain variable region (V_H) in a single polypeptide chain joined by a linker which enables the scFv to form the desired structure for antigen

binding (i.e., for the V_H and V_L of the single polypeptide chain to associate with one another to form a Fv). The V_L and V_H regions may be derived from the parent antibody or may be chemically or recombinantly synthesized.

The term “variable region” is intended to distinguish such domain of the immunoglobulin from domains that are broadly shared by antibodies (such as an antibody Fc domain). The variable region includes a “hypervariable region” whose residues are responsible for antigen binding. The hypervariable region includes amino acid residues from a “Complementarity Determining Region” or “CDR” (i.e., typically at approximately residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and at approximately residues 27-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat *et al.*, *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a “hypervariable loop” (i.e., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, 1987, *J. Mol. Biol.* 196:901-917).

The term “Framework Region” or “FR” residues are those variable domain residues other than the hypervariable region residues as herein defined.

A “neutralizing antibody”, (or an “antibody that neutralized NAMPT activity”), is intended to refer to an antibody whose binding to NAMPT results in inhibition of the biological activity of NAMPT. This inhibition of the biological activity of NAMPT, or its ligands, can be assessed by measuring one or more indicators of NAMPT biological activity, such as quantities of extracellular NAMPT (either *in vitro* or *in vivo*), NAMPT-induced cellular activation and NAMPT binding to NAMPT ligands. These indicators of NAMPT biological activity can be assessed by one or more of several standard *in vitro* or *in vivo* assays known in the art (see Examples). For example, in one embodiment, the ability of an antibody to neutralize NAMPT activity is assessed by inhibition of NAMPT-induced activation of

fibroblasts or endothelial cells. As an additional or alternative parameter of NAMPT activity, the ability of an antibody to inhibit NAMPT-induced transcription activities via NF κ B as a measure of NAMPT-induced cellular activation, can be assessed.

Any form of the “antigen” can be used to generate an antibody that is specific for a target antigen. Thus, the eliciting antigen may contain a single epitope, multiple epitopes, or can be the entire protein alone or in combination with one or more immunogenicity enhancing agents known in the art. The eliciting antigen may be an isolated full-length protein, a cell surface protein (e.g., immunizing with cells transfected with at least a portion of the antigen), or a soluble protein (e.g., immunizing with only the extracellular domain portion of the protein). The antigen may be produced in a genetically modified cell. The DNA encoding the antigen may be genomic or non-genomic (e.g., cDNA). Any genetic vectors suitable for transformation of the cells of interest may be employed, including but not limited to adenoviral vectors, plasmids, and non-viral vectors, such as cationic lipids.

As used herein, the term “specifically binds” refers to the binding of an antibody to its cognate antigen while not significantly binding to other antigens. Preferably, an antibody “specifically binds” to an antigen with an affinity constant (K_a) greater than about 10^5 mol^{-1} (e.g., 10^6 mol^{-1} , 10^7 mol^{-1} , 10^8 mol^{-1} , 10^9 mol^{-1} , 10^{10} mol^{-1} , 10^{11} mol^{-1} , and 10^{12} mol^{-1} or more) with that second molecule.

As used herein, the term “monoclonal antibody” or “MAb” refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules.

As used herein, the terms “inhibit” and “inhibition” mean to decrease an activity, response, condition, disease, or other biological parameter. This can include, but is not limited to, the complete ablation of the activity, response, condition, or disease. This may also include, for example, a 10% reduction in the activity, response, condition, or disease as compared to the

native or control level. Thus, the reduction can be a 10, 20, 30, 40, 50, 60, 70, 80, 90, 100%, or any amount of reduction in between as compared to native or control levels.

As used herein, the term “fusion protein” refers to a polypeptide formed by the joining of two or more polypeptides through a peptide bond formed between the amino terminus of one polypeptide and the carboxyl terminus of another polypeptide or through linking of one polypeptide to another through reactions between amino acid side chains (for example disulfide bonds between cysteine residues on each polypeptide). The fusion protein can be formed by the chemical coupling of the constituent polypeptides or it can be expressed as a single polypeptide from a nucleic acid sequence encoding the single contiguous fusion protein. Fusion proteins can be prepared using conventional techniques in molecular biology to join the two genes in frame into a single nucleic acid sequence, and then expressing the nucleic acid in an appropriate host cell under conditions in which the fusion protein is produced.

As used herein, the term “variant” refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide, but retains essential properties. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more modifications (*e.g.*, substitutions, additions, and/or deletions). A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polypeptide may be naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally.

Modifications and changes can be made in the structure of the polypeptides of in disclosure and still obtain a molecule having similar characteristics as the polypeptide (*e.g.*, a conservative amino acid substitution). For example, certain amino acids can be substituted for other

amino acids in a sequence without appreciable loss of activity. Because it is the interactive capacity and nature of a polypeptide that defines that polypeptide's biological functional activity, certain amino acid sequence substitutions can be made in a polypeptide sequence and nevertheless obtain a polypeptide with like properties.

In making such changes, the hydrophobic index of amino acids can be considered. The importance of the hydrophobic amino acid index in conferring interactive biologic function on a polypeptide is generally understood in the art. It is known that certain amino acids can be substituted for other amino acids having a similar hydrophobic index or score and still result in a polypeptide with similar biological activity. Each amino acid has been assigned a hydrophobic index on the basis of its hydrophobicity and charge characteristics. Those indices are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

It is believed that the relative hydrophobic character of the amino acid determines the secondary structure of the resultant polypeptide, which in turn defines the interaction of the polypeptide with other molecules, such as enzymes, substrates, receptors, antibodies, antigens, and cofactors. It is known in the art that an amino acid can be substituted by another amino acid having a similar hydrophobic index and still obtain a functionally equivalent polypeptide. In such changes, the substitution of amino acids whose hydrophobic indices are within ± 2 is preferred, those within ± 1 are particularly preferred, and those within ± 0.5 are even more particularly preferred.

Substitution of like amino acids can also be made on the basis of hydrophilicity, particularly where the biological functional equivalent polypeptide or peptide thereby created is intended for use in immunological embodiments. The following hydrophilicity values have been assigned to

amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0 \pm 1); glutamate (+3.0 \pm 1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); proline (-0.5 \pm 1); threonine (-0.4); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4). It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent polypeptide. In such changes, the substitution of amino acids whose hydrophilicity values are within \pm 2 is preferred, those within \pm 1 are particularly preferred, and those within \pm 0.5 are even more particularly preferred.

As outlined above, amino acid substitutions are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. Exemplary substitutions that take various of the foregoing characteristics into consideration are well known to those of skill in the art and include (original residue: exemplary substitution): (Ala: Gly, Ser), (Arg: Lys), (Asn: Gln, His), (Asp: Glu, Cys, Ser), (Gln: Asn), (Glu: Asp), (Gly: Ala), (His: Asn, Gln), (Ile: Leu, Val), (Leu: Ile, Val), (Lys: Arg), (Met: Leu, Tyr), (Ser: Thr), (Thr: Ser), (Tyr: Trp, Phe), and (Val: Ile, Leu). Embodiments include functional or biological equivalents of a polypeptide as set forth above. In particular, embodiments of the polypeptides can include variants having about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to the polypeptide of interest. The term “conservative amino acid substitution”, as used herein, is one in which one amino acid residue is replaced with another amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-

branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine).

The term “percent (%) sequence identity” is defined as the percentage of nucleotides or amino acids in a candidate sequence that are identical with the nucleotides or amino acids in a reference nucleic acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full-length of the sequences being compared can be determined by known methods.

For purposes herein, the % sequence identity of a given nucleotides or amino acids sequence C to, with, or against a given nucleic acid sequence D (which can alternatively be phrased as a given sequence C that has or includes a certain % sequence identity to, with, or against a given sequence D) is calculated as follows:

$$100 \text{ times the fraction } W/Z,$$

where W is the number of nucleotides or amino acids scored as identical matches by the sequence alignment program in that program’s alignment of C and D, and where Z is the total number of nucleotides or amino acids in D. It will be appreciated that where the length of sequence C is not equal to the length of sequence D, the % sequence identity of C to D will not equal the % sequence identity of D to C.

The term “ K_{off} ”, is intended to refer to the off rate constant for dissociation of an interaction between a molecule and its ligand, for example, an antibody from the antibody/antigen complex.

The term “ K_d ”, as used herein, is intended to refer to the dissociation constant of a particular antibody-antigen interaction.

The term “myofibroblast accumulation” refers to the presence of fibroblast foci, caused by physiological processes of excessive cellular proliferation, combined reduced apoptosis/programmed cell death in myofibroblasts, and loss of cellular homeostasis/disordered metabolism and dysregulation of certain growth factors.

The terms “monthly dosing regimen”, “monthly dosing”, and “monthly administration”, as used herein, refer to the time course of administering a substance (*e.g.*, an anti-NAMPT antibody) to a subject to achieve a therapeutic objective (*e.g.*, the treatment of a NAMPT -associated disorder). The monthly dosing regimen is not intended to include a weekly dosing regimen. Preferably, the substance is administered every 26-36 days, more preferably, every 28-31 days, even more preferably, every 28-30 days, and most preferably, every 30 days.

The term “human NAMPT” (abbreviated herein as hNAMPT, or simply NAMPT), as used herein, is intended to refer to a human nicotinamide phosphoribosyltransferase enzyme that exists as a 120 kD secreted form, the biologically active form of which is composed of a dimer of noncovalently bound 60 kD molecules. The structure of NAMPT is described further in, for example, Kim, *et al. J Mol Biol.*;362:66–77 (2006). The term NAMPT is intended to include recombinant human NAMPT, which can be prepared by standard recombinant expression methods. The human NAMPT gene is referred to as *NAMPT*.

II. Compositions

Dosage formulations including one or more inhibitors of NAMPT and/or one or more inhibitors of a NAMPT receptor effective to reduce or prevent the development and/or progression of PF in a human have been developed. Compositions for treatment of IPF include: i) inhibitors of the expression and function of the *NAMPT* gene; ii) inhibitors of the enzymatic activity of the NAMPT gene product; iii) manipulation of the interaction of the NAMPT gene product with its receptor, TLR4 (NAMPT/TLR4), iv) neutralization of circulating extracellular NAMPT (eNAMPT); v) manipulation of one or more of the downstream cellular signaling events

associated with NAMPT/TLR4 such as NFκB phosphorylation/activation. Loss of function of the NAMPT gene product gives rise to abnormal function in cellular processes associated with tissue remodeling and scarring, resulting in an associated reduction in the onset, development and severity of IPF in human subjects. Loss of function of the NAMPT gene product gives rise to reduction in myofibroblast accumulation, resulting in an associated reduction cellular processes associated with the onset, development and severity of PF in human subjects.

Compositions for preventing or reducing diseases characterized by myofibroblast accumulation by blockade of expression and/or function of intracellular NAMPT enzyme (iNAMPT) and/or extracellular NAMPT cytokine (eNAMPT) are provided.

A. Targets of Inhibition

1. Nicotinamide Phosphoribosyltransferase (NAMPT)

In some embodiments, the target of inhibition is nicotinamide phosphoribosyltransferase (NAMPT). The NAMPT gene product is the rate-limiting enzyme in the Nicotinamide adenine dinucleotide (NAD⁺) salvage pathway that converts nicotinamide to nicotinamide mononucleotide in mammals to enable NAD⁺ biosynthesis.

The mature form of the extracellular NAMPT protein is a homodimer of approximately 120 kDa, each monomer having approximately 500 amino acid residues (Takahashi, *et al.*, *J.Biochem.* 147: 95-107 (2010)).

It has been established that mutations which reduce or inhibit the function of the NAMPT enzyme reduce or prevent the physiological processes that give rise to PF. It is believed that modulation of the NAMPT enzyme provides a means to modulate physiological processes that give rise to myofibroblast accumulation associated with PF.

a. The NAMPT Gene

The human NAMPT gene (*NAMPT*) is located at chromosome 7, (segment 7q22.3; base pairs 106,248,285 to 106,286,326). Nucleic acid sequences for the human *NAMPT* gene product are known in the art. See, for example, NCBI Reference Sequence: NM_005746.2, Homo sapiens

nicotinamide phosphoribosyltransferase (NAMPT), mRNA, which provides the nucleic acid sequence:

```

ATGAATCCTG CGGCAGAAGC CGAGTTCAAC ATCCTCCTGG CCACCGACTC CTACAAGGTT
ACTCACTATA AACAAATATCC ACCCAACACA AGCAAAGTTT ATTCCTACTT TGAATGCCGT
GAAAAGAAGA CAGAAAACTC CAAATTAAGG AAGGTGAAAT ATGAGGAAAC AGTATTTTAT
GGGTTGCAGT ACATTCTTAA TAAGTACTTA AAAGGTAAAG TAGTAACCAA AGAGAAAATC
CAGGAAGCCA AAGATGTCTA CAAAGAACAT TTCCAAGATG ATGTCTTTAA TGAAAAGGGA
TGGAACTACA TTCTTGAGAA GTATGATGGG CATCTTCCAA TAGAAATAAA AGCTGTTTCT
GAGGGCTTTG TCATTCCCAG AGGAAATGTT CTCTTCACGG TGGAAAACAC AGATCCAGAG
TGTTACTGGC TTACAAATG GATTGAGACT ATTCTTGTTT AGTCTGGTA TCCAATCACA
GTGGCCACAA ATTCTAGAGA GCAGAAGAAA ATATTGGCCA AATATTTGTT AGAAACTTCT
GGTAACTTAG ATGGTCTGGA ATACAAGTTA CATGATTTTG GCTACAGAGG AGTCTCTTCC
CAAGAGACTG CTGGCATAGG AGCATCTGCT CACTTGTTA ACTTCAAAGG AACAGATACA
GTAGCAGGAC TTGCTCTAAT TAAAAAATAT TATGGAACGA AAGATCCTGT TCCAGGCTAT
TCTGTCCAG CAGCAGAACA CAGTACCATA ACAGCTTGGG GGAAAGACCA TGAAAAGAT
GCTTTTGAAC ATATTGTAAC ACAGTTTTCA TCAGTGCCTG TATCTGTGGT CAGCGATAGC
TATGACATTT ATAATGCGTG TGAGAAAATA TGGGGTGAAG ATCTAAGACA TTTAATAGTA
TCGAGAAGTA CACAGGCACC ACTAATAATC AGACCTGATT CTGGAAACCC TCTTGACACT
GTGTTAAAGG TTTTGAGAT TTTAGGTAAG AAGTTTCCTG TTAGTGAGAA CTCAAAGGT
TACAAGTTG TGCCACCTTA TCTTAGAGTT ATTCAAGGGG ATGGAGTAGA TATTAATACC
TTACAAGAGA TTGTAGAAGG CATGAAACAA AAAATGTGGA GTATTGAAA TATTGCCTTC
GGTCTGGTG GAGGTTTGCT ACAGAAAGTTG ACAAGAGATC TCTTGAATG TTCCTTCAAG
TGTAGCTATG TTGTAACTAA TGGCCTTGGG ATTAACGTCT TCAAGGACCC AGTTGCTGAT
CCCAACAAAA GGTCCAAAA GGGCCGATTA TCTTTACATA GGACGCCAGC AGGGAATTTT
GTTACTACTG AGGAAGGAAA AGGAGACCTT GAGGAATATG GTCAGGATCT TCTCCATACT
GTCTTCAAGA ATGGCAAGGT GACAAAAAGC TATTCATTTG ATGAAATAAG AAAAAATGCA
CAGCTGAATA TTGAACTGGA AGCAGCACAT CATTAG
    
```

(SEQ ID NO: 1). Nucleotide sequences that have at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 1 are also disclosed.

b. The NAMPT enzyme

The NAMPT polypeptide is a 473 amino acid cytoplasmic protein (also known as nicotinamide phosphoribosyltransferase, pre-B-cell colony-enhancing factor (PBEF) protein) with a molecular weight of approximately 52,521 Da. There are 3 mRNA variants, with lengths of 2.0, 2.4, and 4.0 kilobases (kb), transcribed by the *NAMPT* gene. The 2.4-kb variant is the most abundant and its open reading frame encodes a protein of 473 amino acids (aa) in length, with a predicted size of approximately 52 kDa (Samal, *et*

al. Mol. Cell. Biol. 14 (2), 1431-1437 (1994)). It has been found in human endothelial cells, where it is able to induce angiogenesis through upregulation of VEGF and VEGFR and secretion of MCP-1. In human umbilical endothelial cells, NAMPT increases levels of the protease MMP 2/9. NAMPT has also been found in a variety of immune cells other than B cells and has been shown to inhibit apoptosis of macrophages and fibroblasts. Extracellular NAMPT (eNAMPT) has been shown to increase NFkB activation and subsequent induction of inflammatory cytokines, such as TNF- α , IL-1 β , IL-16, and TGF- β 1, and the chemokine receptor CCR3. NAMPT also increases the production of IL-6, TNF- α , and IL-1 β in CD14+ monocytes, macrophages, and dendritic cells, enhances the effectiveness of T cells, and is involved in the development of both B and T lymphocytes (Sun, *et al.*, *Cytokine & growth factor reviews* 24(5):433-442 (2013)).

The NAMPT enzyme crystal structure is described in detail in Kim, *et al. J Mol Biol.*;362:66–77 (2006). NAMPT is a dimeric type II phosphoribosyltransferase. The active site of the enzyme is at the dimer interface where the two NAMPT molecules interact. In the apoenzyme structure, a sulfate ion binds in place of the phosphate of NMN. A hydrogen bond between Asp219 and the amide of nicotinamide prevents the enzyme from forming a hydrogen bond to nicotinic or quinolinic acid. Crystal structures of NAMPT are available in the Protein Data Bank as PDB ID Nos. 2G95, 2G96 and 2G97. Amino acid sequences of the human NAMPT enzyme are known in the art. See, for example, GenBank Accession No. NP_005737.1:

```

          10          20          30          40          50
MNPAAEAEFN ILLATDSYKV THYKQYPPNT SKVYSYFECR EKKTENSKLR
          60          70          80          90         100
KVKYEETV FY GLQYILNKYL KGKVVTKKEI QEAKDVYKEH FQDDVFNEKG
          110         120         130         140         150
WNYILEKYDG HLP I E I K A V P E G F V I P R G N V L F T V E N T D P E C Y W L T N W I E T
          160         170         180         190         200
ILVQSWYPIT VATNSREQKK ILAKYLLETS GNLDGLEYKL HDFGYRGVSS

```

210	220	230	240	250
QETAGIGASA	HLVNFKGTDT	VAGLALIKKY	YGTKDPVPGY	SVPAAEHSTI
260	270	280	290	300
TAWGKDHEKD	AFEHIVTQFS	SVPVSVVSDS	YDIYNACEKI	WGEDLRHLIV
310	320	330	340	350
SRSTQAPLII	RPDSGNPLDT	VLKVLEILGK	KFPVTENSKG	YKLLPPYLRV
360	370	380	390	400
IQGDGVDINT	LQEIVEGMKQ	KMWSIENIAF	GSGGGLLQKL	TRDLLNCSEFK
410	420	430	440	450
CSYVVTNGLG	INVFKDPVAD	PNKRSKKGRL	SLHRTPAGNF	VTLEEGKGDLD
460	470	480	490	
EEYGQDLLHT	VFKNGKVTKS	YSFDEIRKNA	QLNIELEAAH	H

(SEQ ID NO: 2)

NAMPT polypeptides that have, for example, at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 2.

The NAMPT enzyme has been associated with many diverse cellular activities, however the biological function of the NAMPT enzyme in the onset and progression of PF remained largely unknown.

The region of dimerization within the mature form of the NAMPT enzyme is described in the X-ray crystal structure of NAMPT, described in Wang, *et al.*, *Nat Struct Mol Biol*, 13, 661-662. (2006). Residues involved in the interface include Ser199 and Ser200.

It may be that the NAMPT protein interacts with one or more ligands through interaction by hydrogen bonding with one or more residues selected from Glu445, Gly446, Lys447, Gly448, Asp449, Leu450, Glu451, Glu452, Tyr453, Gly454, Gln455, Asp456 and Leu457. These residues form a loop that may interact with TLR4 in a manner analogous to MD-2.

2. NAMPT Receptors

In some embodiments, the target of inhibition are the receptors for NAMPT, such as Toll-like receptor 4 (TLR4). Toll-like receptor 4 is a protein that in humans is encoded by the *TLR4* gene. TLR4 is a transmembrane protein, member of the toll-like receptor family, which belongs to the pattern recognition receptor (PRR) family. Its activation leads

to an intracellular NF- κ B signaling pathway and inflammatory cytokine production which is responsible for activating the innate immune system. It is most well known for recognizing lipopolysaccharide (LPS), a component present in many Gram-negative bacteria (*e.g.* *Neisseria* spp.) and select Gram-positive bacteria. Its ligands also include several viral proteins, polysaccharide, and a variety of endogenous proteins such as low-density lipoprotein, beta-defensins, and heat shock protein.

The human TLR4 gene (*TLR4*) is located at chromosome 9, (segment 9q32-q33) (Georgel, *et al.*, *PLoS ONE* 4(11): e7803 (2009)). Nucleic acid sequences for the human *TLR4* gene product are known in the art. See, for example, NCBI Reference Sequence: AAY82268.1, Homo sapiens toll-like receptor 4 (TLR4), mRNA, which provides the nucleic acid sequence:

```

ATGATGTCTG CCTCGCGCCT GGCTGGGACT CTGATCCCAG CCATGGCCTT CCTCTCCTGC
GTGAGACCAG AAAGCTGGGA GCCCTGCGTG GAGGTGGTTC CTAATATTAC TTATCAATGC
ATGGAGCTGA ATTTCTACAA AATCCCCGAC AACCTCCCCT TCTCAACCAA GAACCTGGAC
CTGAGCTTTA ATCCCCTGAG GCATTTAGGC AGCTATAGCT TCTTCAGTTT CCCAGAACTG
CAGGTGCTGG ATTTATCCAG GTGTGAAATC CAGACAATTG AAGATGGGGC ATATCAGAGC
CTAAGCCACC TCTCTACCTT AATATTGACA GGAAACCCCA TCCAGAGTTT AGCCCTGGGA
GCCTTTTCTG GACTATCAAG TTTACAGAAG CTGGTGGCTG TGGAGACAAA TCTAGCATCT
CTAGAGAACT TCCCCATTGG ACATCTCAA ACTTTGAAAG AACTTAATGT GGCTCACAAT
CTTATCCAAT CTTTCAAATT ACCTGAGTAT TTTTCTAATC TGACCAATCT AGAGCACTTG
GACCTTTCCA GCAACAAGAT TCAAAGTATT TATTGCACAG ACTTGCGGGT TCTACATCAA
ATGCCCTAC TCAATCTCTC TTTAGACCTG TCCCTGAACC CTATGAACCT TATCCAACCA
GGTGCATTTA AAGAAATTAG GCTTCATAAG CTGACTTTAA GAAATAATTT TGATAGTTTA
AATGTAATGA AAACCTGTAT TCAAGGTCTG GCTGGTTTAG AAGTCCATCG TTTGGTTCTG
GGAGAATTTA GAAATGAAGG AAACCTGGAA AAGTTTGACA AATCTGCTCT AGAGGGCCTG
TGCAATTTGA CCATTGAAGA ATTCCGATTA GCATACTTAG ACTACTACCT CGATGATATT
ATTGACTTAT TTAATTGTTT GACAAATGTT TCTTCATTTT CCCTGGTGAG TGTGACTATT
GAAAGGGTAA AAGACTTTTC TTATAATTTT GGATGGCAAC ATTTAGAATT AGTTAACTGT
AAATTTGGAC AGTTTCCAC ATTGAAACTC AAATCTCTCA AAAGGCTTAC TTTCACTTCC
AACAAAGGTG GGAATGCTTT TTCAGAAGTT GATCTACCAA GCCTTGAGTT TCTAGATCTC
AGTAGAAATG GCTTGAGTTT CAAAGGTTGC TGTTCTCAA GTGATTTTGG GACAACCAGC
CTAAAGTATT TAGATCTGAG CTTCAATGGT GTTATTACCA TGAGTTCAA CTTCTTGGGC
TTAGAACAAC TAGAACATCT GGATTTCCAG CATTCCAATT TGAAACAAAT GAGTGAGTTT
TCAGTATTCC TATCACTCAG AAACCTCATT TACCTTGACA TTTCTCATA TCACACCAGA
GTTGCTTTCA ATGGCATCTT CAATGGCTTG TCCAGTCTCG AAGTCTTGAA AATGGCTGGC
AATTCCTTCC AGGAAAACCT CCTTCCAGAT ATCTTCACAG AGCTGAGAAA CTTGACCTTC
CTGGACCTCT CTCAGTGTCA ACTGGAGCAG TTGTCTCAA CAGCATTTAA CTCACTCTCC
AGTCTTCAGG TACTAAATAT GAGCCACAAC AACTTCTTTT CATTTGATAC GTTTCCTTAT

```


AAGTGTCTGA ACTCCCTCCA GGTTCCTGAT TACAGTCTCA ATCACATAAT GACTTCCAAA
 AAACAGGAAC TACAGCATTT TCCAAGTAGT CTAGCTTCTT TAAATCTTAC TCAGAATGAC
 TTTGCTTGTA CTTGTGAACA CCAGAGTTTC CTGCAATGGA TCAAGGACCA GAGGCAGCTC
 TTGGTGGGAG TTGAACGAAT GGAATGTGCA ACACCTTCAG ATAAGCAGGG CATGCCTGTG
 CTGAGTTTGA ATATCACCTG TCAGATGAAT AAGACCATCA TTGGTGTGTC GGTCCCTCAGT
 GTGCTGTAG TATCTGTTGT AGCAGTTCTG GTCTATAAGT TCTATTTTCA CCTGATGCTT
 CTTGCTGGCT GCATAAAGTA TGGTAGAGGT GAAAACATCT ATGATGCCTT TGTTATCTAC
 TCAAGCCAGG ATGAGGACTG GGTAAGGAAT GAGCTAGTAA AGAATTTAGA AGAAGGGGTG
 CCTCCATTTT AGCTCTGCCT TCACTACAGA GACTTTTATC CCGGTGTGGC CATTGCTGCC
 AACATCATCC ATGAAGGTTT CCATAAAAGC CGAAAGGTGA TTGTTGTGGT GTCCCAGCAC
 TTCATCCAGA GCCGCTGGTG TATCTTTGAA TATGAGATTG CTCAGACCTG GCAGTTTCTG
 AGCAGTCGTG CTGGTATCAT CTTTATTGTC CTGCAGAAGG TGGAGAAGAC CCTGCTCAGG
 CAGCAGGTGG AGCTGTACCG CCTTCTCAGC AGGAACACTT ACCTGGAGTG GGAGGACAGT
 GTCCTGGGGC GGCACATCTT CTGGAGACGA CTCAGAAAAG CCCTGCTGGA TGGTAAATCA
 TGGAAATCCAG AAGGAACAGT GGGTACAGGA TGCAATTGGC AGGAAGCAAC ATCTATCTGA

(SEQ ID NO: 3). Nucleotide sequences that have at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 3 are also disclosed.

Amino acid sequences of the human TLR4 are known in the art. See, for example, GenBank Accession No. AAY82268.1:

10	20	30	40	50
MMSASRLAGT	LIPAMAF LSC	VRPESWEPCV	EVVFNITYQC	MELNFYKIPD
60	70	80	90	100
NLPFSTKNLD	LSFNPLRHLG	SYSFFSFPEL	QVLDLSRCEI	QTIEDGAYQS
110	120	130	140	150
LSHLSTLILT	GNPIQSLALG	AFSGLSSLQK	LVAVETNLAS	LENFPIGHLK
160	170	180	190	200
TLKELNVAHN	LIQSFKLPEY	FSNLTNLEHL	DLSSNKIQSI	YCTDLRVLHQ
210	220	230	240	250
MPLLNLSDL	SLNPMNFIQP	GAFKEIRLHK	LTLRNNFDSL	NVMKTCIQGL
260	270	280	290	300
AGLEVHRLVL	GEFRNEGNLE	KFDKSALEGL	CNLTIEEFRL	AYLDYYLDDI
310	320	330	340	350
IDLFNCLTNV	SSFSLVSVTI	ERVKDFSYNF	GWQHLELVNC	KFGQFP TLKL
360	370	380	390	400
KSLKRLTFTS	NKGGNAFSEV	DLPSLEFLDL	SRNGLSFKGC	CSQSDFGTTS

410	420	430	440	450
LKYLDLSFNG	VITMSSNFLG	LEQLEHLDFQ	HSNLKQMSEF	SVFLSLRNLI
460	470	480	490	500
YLDISHTHTR	VAFNGIFNGL	SSLEVLKMAG	NSFQENFLPD	IFTELRNLTF
510	520	530	540	550
LDLSQCQLEQ	LSPTAFNSLS	SLQVLNMSHN	NFFSLDTFPY	KCLNSLQVLD
560	570	580	590	600
YSLNHIMTSK	KQELQHFPSS	LAFNLNTQND	FACTCEHQSF	LQWIKDQRQL
610	620	630	640	650
LVEVERMECA	TPSDKQGMPV	LSLNITCQMN	KTIIGVSVLS	VLVVSVAVL
660	670	680	690	700
VYKFYFHLML	LAGCIKYGRG	ENIYDAFVIY	SSQDEDWVRN	ELVKNLEEGV
710	720	730	740	750
PPFQLCLHYR	DFIPGVAIAA	NIIHEGFHKS	RKVIVVVSQH	FIQSRWCIFE
760	770	780	790	800
YEIAQTWQFL	SSRAGIIFIV	LQKVEKTLR	QQVELYRLLS	RNTYLEWEDS
810	820	830		
VLGRHIFWRR	LRKALLDGKS	WNPEGTVGTG	CNWQEATSI	

(SEQ ID NO: 4).

TLR4 polypeptides that have at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO: 4 are described.

Lymphocyte antigen 96, also known as “MD2” is a protein that is associated with TLR4 on the cell surface and enables TLR4 to respond to LPS. MD-2 also enables TLR4 to respond to a wide variety of endotoxic LPS partial structures, Gram-negative bacteria, and Gram-positive lipoteichoic acid, but not to Gram-positive bacteria, peptidoglycan, and lipopeptide. MD-2 physically associates with TLR4 and TLR2, but the association with TLR2 is weaker than with TLR4. MD-2 and TLR4 enhance each other's expression (Dziarski, *et al.*, *J Endotoxin Res.* 6(5):401-5 (2000)).

It has been established that TLR4 is a receptor for extracellular NAMPT (eNAMPT) (Camp *et al.*, *Sci Rep.* 5:13135 (2015)). It may be that eNAMPT binds to TLR4 in the region of the interaction with MD2. Therefore, antibodies, small molecules and functional nucleic acids that bind to TLR4 in the region of the interaction with MD2 are described.

B. Inhibitors of NAMPT and NAMPT Receptors

Blockade of the NAMPT expression and/or function of NAMPT can reduce or prevent immune processes that give rise to the onset and development of chronic and acute PF. Agents that inhibit or reduce the transcription, translation or function of the NAMPT enzyme, or which inhibit the interaction of NAMPT with TLR4 (NAMPT/TLR4) are described.

Inhibitors of NAMPT can bind to the NAMPT gene or to NAMPT polypeptide and directly or indirectly block the biological function of NAMPT polypeptide. Inhibitors can also block the biological function of one or more signaling pathways that constitute the down-stream biological function of NAMPT. In some embodiments, inhibitors of NAMPT act by preventing endogenous receptors of the NAMPT polypeptide from interacting with or binding directly to the NAMPT polypeptide. The inhibitors can block protein-protein interactions involving the NAMPT polypeptide, or they can prevent or reduce the functional activity of a complex of the NAMPT enzyme and a receptors. Inhibitors that bind directly to the NAMPT polypeptide may act by direct occlusion of an active site on the NAMPT polypeptide, or through indirect occlusion, such as by steric blockade of NAMPT interactions. For example, in some embodiments the inhibitor obstructs or occludes the function of a protein interaction domain, such as the enzyme active site, or the site of homo-dimerization between two NAMPT monomers within the active NAMPT polypeptide, or the site of interaction with a receptor, for example, the site of interaction with TLR4. In other embodiments, inhibitors bind to a location that is spatially distinct from an active site. Therefore, in certain embodiments, inhibitors that bind to the NAMPT polypeptide can prevent NAMPT function by mechanisms including, but not limited to, preventing or disrupting dimerization, inducing oligomerization, inducing conformational changes, preventing catalytic functions, inducing degradation, inducing uptake by immune cells, preventing uptake by target cells, preventing ligand binding, preventing phosphorylation, inducing denaturation, preventing one or more post-translational modifications or otherwise altering the native tertiary structure

of the NAMPT polypeptide.

It is understood that initiation or transduction of cellular signaling pathways by NAMPT can require binding of a receptor by the NAMPT polypeptide. Therefore, proteins, antibodies or small molecules that block signal transduction pathways involving NAMPT and optionally prevent co-ligation of NAMPT and its receptors are useful immune-modulatory agents. Classes of NAMPT inhibitors discussed below include antibodies, Fab fractions of antibodies and functional nucleic acids that bind directly to the NAMPT polypeptide, as well as antibodies, Fab fractions of antibodies and functional nucleic acids that bind to ligands of NAMPT.

1. Antibodies

Antibodies that inhibit the function of NAMPT by specific interaction directly with the NAMPT enzyme, its receptors, or its accessory molecules are provided. Antibodies can include an antigen binding site that binds to an epitope on the NAMPT enzyme. Binding of an antibody to NAMPT can inhibit or reduce the function of the NAMPT enzyme *via* one or more distinct mechanisms. Typically, the antibodies can reduce or neutralize NAMPT biological activity *in vitro* and *in vivo*. In some embodiments, the antibodies have high affinity for NAMPT (*e.g.*, $K_d = 10^{-8}$ M or less), a slow off rate for NAMPT dissociation (*e.g.*, $K_{off} = 10^{-3}$ sec⁻¹, or less), or a combination thereof.

Full-length antibodies, antigen binding fragments thereof, and fusion proteins based thereon are provided. Useful antibodies, and antigen-binding fragments thereof are typically characterized by binding to NAMPT, or one or more ligands of NAMPT, preferably with high affinity and slow dissociation kinetics. In some embodiments, the antibodies, or antigen-binding fragments thereof inhibit NAMPT activity, including NAMPT-induced transcription through NF κ B (*in vitro* and *in vivo*) and NAMPT-induced cellular activation. The antibodies can be full-length (*e.g.*, an IgG subtype 1, or IgG4 antibody) or can comprise only an antigen-binding portion (*e.g.*, a Fab, F(ab')₂ scFv fragment, or F(Ab) single domain). An

exemplary recombinant antibody binds an epitope including two or more of the amino acid residues set forth in SEQ ID NO. 2.

In some embodiments, inhibitors of NAMPT, or ligands of NAMPT, are proteins that have the antigen-binding specificity of an antibody, such as a fragment of an antibody. The term “antigen-binding portion” of an antibody (or simply “antibody portion”), refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (*e.g.*, NAMPT).

Various types of antibodies and antibody fragments can be used in the disclosed compositions and methods, including whole immunoglobulin of any class, fragments thereof, and synthetic proteins containing at least the antigen binding variable domain of an antibody. The antibody can be an IgG antibody, such as IgG₁, IgG₂, IgG₃, or IgG₄. An antibody can be in the form of an antigen binding fragment including a Fab fragment, F(ab')₂ fragment, a single chain variable region, and the like. Antibodies can be polyclonal or monoclonal (mAb).

Monoclonal antibodies include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they specifically bind the target antigen and/or exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison, et al., *Proc. Natl. Acad. Sci. USA*, 81: 6851-6855 (1984)).

The antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term “antigen binding portion” of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')₂ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd

fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and VH domains of a single arm of an antibody, (v) a dAb fragment (Ward et al., (1989) Nature 341 :544-546), which consists of a VH domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term “antigen-binding portion” of an antibody. Other forms of single chain antibodies, such as diabodies, are also encompassed. Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites.

a. Characteristics of the Antibodies

In some embodiments, the antibody or antigen binding fragment binds specifically to an epitope within the protein encoded by the amino acid sequence of SEQ ID NO: 2. A linear epitope is an epitope that formed by a continuous sequence of amino acids from the antigen. Linear epitopes typically include approximately 5 to about 10 continuous amino acid residues. Antibodies bind a linear epitope based on the primary sequence of the antigen. Thus, in some embodiments, the epitope can be a linear epitope and can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more consecutive amino acids of the primary sequence of SEQ ID NO: 2. A “conformational epitope” is an epitope that includes discontinuous sections of the antigen's amino acid sequence. Antibodies bind a conformational epitope based on 3-D surface features, shape, or tertiary structure of the antigen. Thus, in some embodiments, the antibody or antigen binding fragment thereof can bind a

conformational epitope that includes a 3-D surface feature, shape, or tertiary structure of the NAMPT enzyme. In some embodiments, a 3-D surface feature can include any number of amino acids from SEQ ID NO: 2, or the corresponding residues in a homolog, ortholog, paralog, or variant thereof.

In some embodiments, the antibody or antigen binding fragment thereof interferes with the interaction between NAMPT and TLR4. NAMPT may bind to TLR4 through a binding loop including some or all of the residues in the amino acid sequence EGKGDLEEYGHDL (SEQ ID NO:5) corresponding with amino acids 445 through 457 of SEQ ID NO:2. In some embodiments, SEQ ID NO: 5 serves as part or all of an antigen for producing an anti-NAMPT antibody. In some embodiments, SEQ ID NO: 5, or residues thereof, form part or all of the epitope to which the antibody binds. In some embodiments, SEQ ID NO: 5 forms part or all of a conformation epitope.

In some embodiments, the antibody or antigen binding fragment that binds specifically to an epitope within the protein encoded by the amino acid sequence of SEQ ID NO: 2 can only bind if the protein encoded by the amino acid sequence of SEQ ID NO: 2 is not bound by a ligand or small molecule.

In some embodiments, the antibody or antigen binding portion thereof dissociates from human NAMPT, or a ligand of human NAMPT, with a K_{off} rate constant of $1 \times 10^{-1}/\text{s}^{-1}$ or less. Preferably, the antibody, or antigen-binding portion thereof, dissociates from human NAMPT, or a ligand of human NAMPT with a K_{off} rate constant of $5 \times 10^{-4}/\text{s}^{-1}$ or less. Even more preferably, the antibody, or antigen binding portion thereof, dissociates from human NAMPT, or a ligand of human NAMPT with a K_{off} rate constant of $1 \times 10^{-4}/\text{s}^{-1}$ or less or less. Typically, the anti-NAMPT antibody binds an epitope formed by two or more amino acid residues at the surface of the tertiary structure of the NAMPT enzyme formed by the amino acid sequence of SEQ ID NO. 2. Exemplary suitable antibodies are also discussed in U.S. Patent No. 9,409,983.

Commercial antibodies specific for NAMPT are available. For example, polyclonal and monoclonal rabbit, mouse or rat anti-human NAMPT antibodies are commercially available from multiple vendors (*e.g.*, Rabbit anti-human NAMPT polyclonal Antibody (Thermo-Fischer scientific Catalog # PA5-34858); or mouse anti-human NAMPT monoclonal antibody 1D3A12 (Thermo-Fischer scientific Catalog # MA5-15388); or rat anti-human NAMPT monoclonal antibody 362616 (Thermo-Fischer scientific Catalog # MA5-24108)).

Rabbit and mouse polyclonal and monoclonal anti-human TLR4 antibodies are commercially available from multiple vendors (*e.g.*, Rabbit anti-human TLR4 polyclonal Antibody (Thermo-Fischer scientific Catalog # 48-2300); or mouse anti-human TLR4 monoclonal antibody HTA125 (Thermo-Fischer scientific Catalog # 14-9917-82); or mouse polyclonal antibody (Thermo-Fischer scientific Catalog # 36-3700)).

In some embodiments, a commercially available antibody is used. In some embodiments, the antibody utilized in the disclosed compositions and methods is a humanized or chimeric antibody or an antigen-binding fragment thereof (*e.g.*, a single chain antibody), having one, two, three, four, five, or six CDRs from a commercially available antibody, or having variant CDRs thereof having 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, or 99 percent sequence identity to the corresponding CDRs of commercially available antibody.

In some embodiments, the antibody has the same epitope specificity as a commercially available anti-NAMPT antibody or anti-TLR4 antibody or an anti-NAMPT antibody or anti-TLR4 antibody that is otherwise known in the art. This can be achieved by producing a recombinant antibody that contains the paratope of the commercially or otherwise available antibody.

b. Antibody Composition and Methods of Manufacture

To prepare an antibody that specifically binds to NAMPT or a receptor thereof, purified polypeptides, fragments, fusions, or epitopes thereof, or polypeptides expressed from their nucleic acid sequences, can be used. Using the purified NAMPT or NAMPT ligand polypeptides, or

receptor fragments, fusions, or epitopes thereof or proteins expressed from their nucleic acid sequences, antibodies can be prepared using any suitable methods known in the art.

The antibodies can be generated in cell culture, in phage, or in various animals, including mice, rabbits, sheep and horses. Therefore, in some embodiments, an antibody is a mammalian antibody. Phage techniques can be used to isolate an initial antibody or to generate variants with altered specificity or avidity characteristics. Such techniques are routine and well known in the art. In one embodiment, the antibody is produced by recombinant means known in the art. For example, a recombinant antibody can be produced by transfecting a host cell with a vector comprising a DNA sequence encoding the antibody. One or more vectors can be used to transfect the DNA sequence expressing at least one VL and one VH region in the host cell. Exemplary descriptions of recombinant means of antibody generation and production include Delves, *Antibody Production: Essential Techniques* (Wiley, 1997); Shephard, et al., *Monoclonal Antibodies* (Oxford University Press, 2000); Goding, *Monoclonal Antibodies: Principles And Practice* (Academic Press, 1993); *Current Protocols In Immunology* (John Wiley & Sons, most recent edition).

The antibodies can be modified by recombinant means to increase efficacy of the antibody in mediating the desired function. The antibodies can be modified by substitutions using recombinant means. Typically, the substitutions will be conservative substitutions. For example, at least one amino acid in the constant region of the antibody can be replaced with a different residue. See, e.g., U.S. Pat. No. 5,624,821, U.S. Pat. No. 6,194,551, Application No. WO 9958572; and Angal, et al., *Mol. Immunol.* 30:105-08 (1993). The modification in amino acids includes deletions, additions, substitutions of amino acids. In some cases, such changes are made to reduce undesired activities, e.g., complement-dependent cytotoxicity. Frequently, the antibodies are labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both

the scientific and patent literature. These antibodies can be screened for binding to NAMPT or NAMPT ligand polypeptides, or fragments, or fusions thereof. See e.g., *Antibody Engineering: A Practical Approach* (Oxford University Press, 1996).

Suitable antibodies with the desired biologic activities can be identified by *in vitro* assays including but not limited to: proliferation, migration, adhesion, soft agar growth, angiogenesis, cell-cell communication, apoptosis, transport, signal transduction, and the following *in vivo* assays such as the inhibition of tumor growth.

Antibodies that can be used in the disclosed compositions and methods include whole immunoglobulin (i.e., an intact antibody) of any class, fragments thereof, and synthetic proteins containing at least the antigen binding variable domain of an antibody. The variable domains differ in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each include four FR regions, largely adopting a beta-sheet configuration, connected by three CDRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies.

Also disclosed are fragments of antibodies which have bioactivity. The fragments, whether attached to other sequences or not, include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment.

Techniques can also be adapted for the production of single-chain antibodies specific to an antigenic protein. Methods for the production of single-chain antibodies are well known to those of skill in the art. A single chain antibody can be created by fusing together the variable domains of the heavy and light chains using a short peptide linker, thereby reconstituting an antigen binding site on a single molecule. Single-chain antibody variable fragments (scFvs) in which the C-terminus of one variable domain is tethered to the N-terminus of the other variable domain via a 15 to 25 amino acid peptide or linker have been developed without significantly disrupting antigen binding or specificity of the binding. The linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation.

Divalent single-chain variable fragments (di-scFvs) can be engineered by linking two scFvs. This can be done by producing a single peptide chain with two VH and two VL regions, yielding tandem scFvs. ScFvs can also be designed with linker peptides that are too short for the two variable regions to fold together (about five amino acids), forcing scFvs to dimerize. This type is known as diabodies. Diabodies have been shown to have dissociation constants up to 40-fold lower than corresponding scFvs, meaning that they have a much higher affinity to their target. Still shorter linkers (one or two amino acids) lead to the formation of trimers (tribodies or tribodies). Tetrabodies have also been produced. They exhibit an even higher affinity to their targets than diabodies.

A monoclonal antibody is obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. Monoclonal antibodies include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies

derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity.

Monoclonal antibodies can be made using any procedure which produces monoclonal antibodies. In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

Antibodies may also be made by recombinant DNA methods. DNA encoding the disclosed antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques.

i. Human and Humanized Antibodies

Many non-human antibodies (e.g., those derived from mice, rats, or rabbits) are naturally antigenic in humans, and thus can give rise to undesirable immune responses when administered to humans. Therefore, the use of human or humanized antibodies in the methods serves to lessen the chance that an antibody administered to a human will evoke an undesirable immune response.

Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge.

Optionally, the antibodies are generated in other species and “humanized” for administration in humans. Humanized forms of non-human

(e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')₂, or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient antibody are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also contain residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will contain substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will contain at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Humanization can be essentially performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, a humanized form of a non-human antibody (or a fragment thereof) is a chimeric antibody or fragment, wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized

antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important in order to reduce antigenicity. According to the “best-fit” method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody. Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework may be used for several different humanized antibodies.

Sometimes, CDR-grafting alone can lead to a reduction or complete loss of binding affinity, as a set of supporting framework residues in the Vernier zone are important for maintaining the conformation of the CDRs (Foote and Winter, *J. Mol. Bio.*, 224:487-499 (1992)). This problem can be addressed by reintroducing murine residues into the human framework (Queen, et al., *Proc. Natl. Acad. Sci. USA*, 86(24):10029-33 (1989)); such substitutions are commonly called back-mutations.

Most therapeutic proteins are, to a varying extent, immunogenic (Van Walle et al., *Expert Opin. Biol., Ther.*, 7:405-418 (2007), Stas et al., Cambridge University Press, Cambridge, (2009)) and even so called fully-human antibody therapeutics may contain immunogenic regions (Harding et al., *J. Chromatogr. B. Biomed. Sci. Appl.*, 752:233-245 (2001)).

Immunogenicity is the ability to induce a Th (T-helper) response, which is triggered when a unique T-cell receptor recognizes a peptide bound to the HLA class II molecules displayed on antigen presenting cells. The peptides are generated from proteins internalized by the antigen presenting cell which are then processed through the endosomal cleavage pathway. Only peptides with sufficient affinity for the HLA class II molecules will be presented on the cell surface, and could possibly trigger a Th response.

Consequently, it is possible to lower the immunogenicity potential by removing Th epitopes, a process known as deimmunization (Chamberlain, *The Regulatory Review*, 5:4-9 (2002), Baker and Jones, *Curr. Opin. Drug. Discov. Devel.*, 10:219-227 (2007)). This is achieved by predicting which peptides in the therapeutic protein can bind to HLA class II molecules, and subsequently introducing substitutions that eliminate or reduce the peptide binding affinity for HLA class II molecules.

There are several HLA class II genes and almost all are highly polymorphic. Additionally, HLA class II molecules consist of an alpha and beta chain, each derived from a different gene which, with the inherent polymorphism, further increases variation. Every individual expresses the genes: DRA/DRB, DQA/DQB and DPA/DPB. Of these only DRA is non-polymorphic. In addition, a 'second' DRB gene (DRB3, DRB4 or DRB5) may also be present, the product of which also associates with the DRA chain.

The focus during a deimmunization is on the DR allotypes, which are known to express at a higher level than DQ and DP (Laupeze et al., *Hum. Immunol.*, 61:591-97 (1999), Gansbacher and Zier, *Cell Immunol.*, 117:22-34 (1988), Berdoz, et al., *J. Immunol.*, 139:1336-1341 (1987), Stunz et al., "HLA-DRB1 and -DRB4 genes are differentially regulated at the transcriptional level, *J. Immunol.*, 143:3081-3086 (1989)). The assessment of severity for individual epitopes is based on the criteria of promiscuity, i.e., the number of HLA allotypes a specific epitope binds to, as well as the importance (frequency) of the allotypes in the population and a qualitative assessment of the HLA:peptide complex binding strength. As the T-cell population of an individual has been selected to not recognize "self-peptides" it is possible to screen the protein that is being deimmunized for peptides that correspond to (known) self-peptides which should not normally induce a Th response.

Because an important property of a therapeutic antibody is the binding activity, it is important that substitutions proposed during the humanization and deimmunization do not substantially affect the affinity or

stability of the antibody. A large amount of information has been collected in the last 20 years on humanization and grafting of the CDRs (Jones et al., *Nature*, 321, 522-525 (1986), Foote and Winter, *J. Mol. Biol.*, 224:487-499 (1992)), the biophysical properties of antibodies (Ewert et al., *J. Mol. Biol.*, 325:531-553 (2003)), the conformation of the CDR-loops (Chothia and Lesk, *J. Mol. Biol.*, 196:901-917 (1987), Al-Lazikani, et al., *J. Mol. Biol.*, 273:927-948 (1997), North, et al., *J. Mol. Biol.*, 406:228-256 (2011)) and for the frameworks (Vargas-Madrado and Paz-García, *J. Mol. Recognit.*, 16:113-120 (2003), Honegger, et al., *Protein Eng. Des. Sel.*, 22:121-134 (2009)), which along with advances in protein modeling (Desmet, et al., *Proteins*, 48:31-43 (2002), Almagro, et al., *Proteins*, 79:3050-3066 (2011)) makes it possible to accurately humanize and deimmunize antibodies with substantially retained binding affinity and stability.

For example, humanized antibodies can be prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen. In this way, FR residues can be selected and combined from the consensus and import sequence so that the desired antibody characteristic, such as increased affinity for the target antigen(s), is achieved. In general, the CDR residues are directly and most substantially involved in influencing antigen binding.

ii. Single-Chain Antibodies

Methods for the production of single-chain antibodies are well known to those of skill in the art. A single chain antibody is created by fusing together the variable domains of the heavy and light chains using a short

peptide linker, thereby reconstituting an antigen binding site on a single molecule. Single-chain antibody variable fragments (scFvs) in which the C-terminus of one variable domain is tethered to the N-terminus of the other variable domain via a 15 to 25 amino acid peptide or linker have been developed without significantly disrupting antigen binding or specificity of the binding. The linker is chosen to permit the heavy chain and light chain to bind together in their proper conformational orientation. These Fvs lack the constant regions (Fc) present in the heavy and light chains of the native antibody.

iii. Monovalent Antibodies

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment, called the F(ab')₂ fragment, that has two antigen combining sites and is still capable of cross-linking antigen.

The Fab fragments produced in the antibody digestion also contain the constant domains of the light chain and the first constant domain of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain domain including one or more cysteines from the antibody hinge region. The F(ab')₂ fragment is a bivalent fragment comprising two Fab' fragments linked by a disulfide bridge at the hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. Antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

iv. Hybrid antibodies

The antibody can be a hybrid antibody. In hybrid antibodies, one heavy and light chain pair is homologous to that found in an antibody raised against one epitope, while the other heavy and light chain pair is homologous to a pair found in an antibody raised against another epitope. This results in the property of multi-functional valency, i.e., a bivalent antibody has the ability to bind at least two different epitopes simultaneously. Such hybrids can be formed by fusion of hybridomas producing the respective component antibodies, or by recombinant techniques. Such hybrids may, of course, also be formed using chimeric chains.

v. Conjugates or Fusions of Antibody Fragments

The targeting function of the antibody can be used therapeutically by coupling the antibody or a fragment thereof with a therapeutic agent. Such coupling of the antibody or fragment (e.g., at least a portion of an immunoglobulin constant region (Fc)) with the therapeutic agent can be achieved by making an immunoconjugate or by making a fusion protein, comprising the antibody or antibody fragment and the therapeutic agent.

Such coupling of the antibody or fragment with the therapeutic agent can be achieved by making an immunoconjugate or by making a fusion protein, or by linking the antibody or fragment to a nucleic acid such as an siRNA, comprising the antibody or antibody fragment and the therapeutic agent.

In some embodiments, the antibody is modified to alter its half-life. In some embodiments, it is desirable to increase the half-life of the antibody so that it is present in the circulation or at the site of treatment for longer periods of time. For example, it may be desirable to maintain titers of the antibody in the circulation or in the location to be treated for extended periods of time. Antibodies can be engineered with Fc variants that extend half-life, e.g., using Xtend™ antibody half-life prolongation technology (Xencor, Monrovia, CA). In other embodiments, the half-life of the anti-DNA antibody is decreased to reduce potential side effects. The conjugates

disclosed can be used for modifying a given biological response. The drug moiety is not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin.

vi. Method of Making Antibodies Using Protein Chemistry

One method of producing proteins such as antibodies is to link two or more peptides or polypeptides together by protein chemistry techniques. For example, peptides or polypeptides can be chemically synthesized using currently available laboratory equipment using either Fmoc (9-fluorenylmethyloxycarbonyl) or Boc (tert -butyloxycarbonyl) chemistry. (Applied Biosystems, Inc., Foster City, CA). One skilled in the art can readily appreciate that a peptide or polypeptide corresponding to the antibody, for example, can be synthesized by standard chemical reactions. For example, a peptide or polypeptide can be synthesized and not cleaved from its synthesis resin whereas the other fragment of an antibody can be synthesized and subsequently cleaved from the resin, thereby exposing a terminal group which is functionally blocked on the other fragment. By peptide condensation reactions, these two fragments can be covalently joined via a peptide bond at their carboxyl and amino termini, respectively, to form an antibody, or fragment thereof. Alternatively, the peptide or polypeptide is independently synthesized *in vivo* as described above. Once isolated, these independent peptides or polypeptides may be linked to form an antibody or antigen binding fragment thereof via similar peptide condensation reactions. For example, enzymatic ligation of cloned or synthetic peptide segments allow relatively short peptide fragments to be joined to produce larger peptide fragments, polypeptides or whole protein domains. Alternatively, native chemical ligation of synthetic peptides can be utilized to synthetically construct large peptides or polypeptides from shorter peptide fragments. This method consists of a two-step chemical reaction. The first step is the

chemoselective reaction of an unprotected synthetic peptide-alpha-thioester with another unprotected peptide segment containing an amino-terminal Cys residue to give a thioester-linked intermediate as the initial covalent product. Without a change in the reaction conditions, this intermediate undergoes spontaneous, rapid intramolecular reaction to form a native peptide bond at the ligation site.

2. Functional Nucleic Acids

Functional nucleic acids that inhibit the transcription, translation or function of the *NAMPT* gene are disclosed. Functional nucleic acids are nucleic acid molecules that have a specific function, such as binding a target molecule or catalyzing a specific reaction. As discussed in more detail below, functional nucleic acid molecules can be divided into the following non-limiting categories: antisense molecules, siRNA, miRNA, aptamers, ribozymes, triplex forming molecules, RNAi, and external guide sequences. The functional nucleic acid molecules can act as effectors, inhibitors, modulators, and stimulators of a specific activity possessed by a target molecule, or the functional nucleic acid molecules can possess a *de novo* activity independent of any other molecules.

Functional nucleic acid molecules can interact with any macromolecule, such as DNA, RNA, polypeptides, or carbohydrate chains. Thus, functional nucleic acids can interact with the mRNA or the genomic DNA of the *NAMPT* gene or they can interact with the *NAMPT* polypeptide itself. Functional nucleic acids are often designed to interact with other nucleic acids based on sequence homology between the target molecule and the functional nucleic acid molecule. In other situations, the specific recognition between the functional nucleic acid molecule and the target molecule is not based on sequence homology between the functional nucleic acid molecule and the target molecule, but rather is based on the formation of tertiary structure that allows specific recognition to take place. Therefore the disclosed compositions can include one or more functional nucleic acids designed to reduce expression or function of the *NAMPT* enzyme.

In some embodiments, the composition includes a functional nucleic acid or polypeptide designed to target and reduce or inhibit expression or translation of NAMPT mRNA; or to reduce or inhibit expression, reduce activity, or increase degradation of NAMPT enzyme. In some embodiments, the composition includes a vector suitable for *in vivo* expression of the functional nucleic acid.

In some embodiments, a functional nucleic acid or polypeptide is designed to target a segment of the nucleic acid encoding the amino acid sequence of SEQ ID NO: 2, or the complement thereof, or variants thereof having a nucleic acid sequence 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to a nucleic acid encoding the amino acid sequence of SEQ ID NO: 2.

In other embodiments, a functional nucleic acid or polypeptide is designed to target a segment of the nucleic acid sequence of SEQ ID NO: 1, or the complement thereof, or variants thereof having a nucleic acid sequence at least 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identical to SEQ ID NO: 1.

In some embodiments, the function nucleic acid hybridizes to the nucleic acid of SEQ ID NO: 1, or a complement thereof, for example, under stringent conditions. In some embodiments, the function nucleic acid hybridizes to a nucleic acid sequence that encodes SEQ ID NO: 2, or a complement thereof, for example, under stringent conditions.

Methods of making and using vectors for *in vivo* expression of the disclosed functional nucleic acids such as antisense oligonucleotides, siRNA, shRNA, miRNA, EGSs, ribozymes, and aptamers are known in the art.

i. Antisense Molecules

The functional nucleic acids can be antisense molecules. Antisense molecules are designed to interact with a target nucleic acid molecule through either canonical or non-canonical base pairing. The interaction of the antisense molecule and the target molecule is designed to promote the

destruction of the target molecule through, for example, RNase H mediated RNA-DNA hybrid degradation. Alternatively the antisense molecule is designed to interrupt a processing function that normally would take place on the target molecule, such as transcription or replication. Antisense molecules can be designed based on the sequence of the target molecule. There are numerous methods for optimization of antisense efficiency by finding the most accessible regions of the target molecule. Exemplary methods include *in vitro* selection experiments and DNA modification studies using DMS and DEPC. It is preferred that antisense molecules bind the *NAMPT* target molecule with a dissociation constant (K_d) less than or equal to 10^{-6} , 10^{-8} , 10^{-10} , or 10^{-12} .

ii. Aptamers

The functional nucleic acids can be aptamers. Aptamers are molecules that interact with a target molecule, preferably in a specific way. Typically aptamers are small nucleic acids ranging from 15-50 bases in length that fold into defined secondary and tertiary structures, such as stem-loops or G-quartets. Aptamers can bind small molecules, such as ATP and theophylline, as well as large molecules, such as reverse transcriptase and thrombin. Aptamers can bind very tightly with K_d 's from the target molecule of less than 10^{-12} M. It is preferred that the aptamers bind the *NAMPT* target molecule with a K_d less than 10^{-6} , 10^{-8} , 10^{-10} , or 10^{-12} . Aptamers can bind the target molecule with a very high degree of specificity. For example, aptamers have been isolated that have greater than a 10,000 fold difference in binding affinities between the target molecule and another molecule that differ at only a single position on the molecule. It is preferred that the aptamer have a K_d with the *NAMPT* target molecule at least 10, 100, 1000, 10,000, or 100,000 fold lower than the K_d with a background binding molecule. It is preferred when doing the comparison for a molecule such as a polypeptide, that the background molecule be a different polypeptide.

iii. Ribozymes

The functional nucleic acids can be ribozymes. Ribozymes are nucleic acid molecules that are capable of catalyzing a chemical reaction,

either intra-molecularly or inter-molecularly. It is preferred that the ribozymes catalyze intermolecular reactions. Different types of ribozymes that catalyze nuclease or nucleic acid polymerase-type reactions which are based on ribozymes found in natural systems, such as hammerhead ribozymes are disclosed. Ribozymes that are not found in natural systems, but which have been engineered to catalyze specific reactions *de novo* are also disclosed. Preferred ribozymes cleave RNA or DNA substrates, and more preferably cleave RNA substrates. Ribozymes typically cleave nucleic acid substrates through recognition and binding of the target substrate with subsequent cleavage. This recognition is often based mostly on canonical or non-canonical base pair interactions. This property makes ribozymes particularly good candidates for targeting specific cleavage of nucleic acids because recognition of the target substrate is based on the target substrates sequence.

iv. Triplex Forming Oligonucleotides

The functional nucleic acids can be triplex forming oligonucleotide molecules. Triplex forming functional nucleic acid molecules are molecules that can interact with either double-stranded or single-stranded nucleic acid. When triplex molecules interact with a target region, a structure called a triplex is formed in which there are three strands of DNA forming a complex dependent on both Watson-Crick and Hoogsteen base-pairing. Triplex molecules are preferred because they can bind target regions with high affinity and specificity. It is preferred that the triplex forming molecules bind the target molecule with a K_d less than 10^{-6} , 10^{-8} , 10^{-10} , or 10^{-12} .

v. External Guide Sequences

The functional nucleic acids can be external guide sequences. External guide sequences (EGSs) are molecules that bind a target nucleic acid molecule forming a complex, which is recognized by RNase P, which then cleaves the target molecule. EGSs can be designed to specifically target a RNA molecule of choice. RNase P aids in processing transfer RNA (tRNA) within a cell. Bacterial RNase P can be recruited to cleave virtually any RNA sequence by using an EGS that causes the target RNA:EGS

complex to mimic the natural tRNA substrate. Similarly, eukaryotic EGS/RNase P-directed cleavage of RNA can be utilized to cleave desired targets within eukaryotic cells. Representative examples of how to make and use EGS molecules to facilitate cleavage of a variety of different target molecules are known in the art.

vi. RNA Interference

In some embodiments, the functional nucleic acids induce gene silencing through RNA interference (siRNA). Expression of the *NAMPT* gene can be effectively silenced in a highly specific manner through RNA interference.

Gene silencing was originally observed with the addition of double stranded RNA (dsRNA) (Fire, *et al.* (1998) *Nature*, 391:806-11; Napoli, *et al.* (1990) *Plant Cell* 2:279-89; Hannon, (2002) *Nature*, 418:244-51). Once dsRNA enters a cell, it is cleaved by an RNase III-like enzyme called Dicer, into double stranded small interfering RNAs (siRNA) 21-23 nucleotides in length that contain 2 nucleotide overhangs on the 3' ends (Elbashir, *et al.*, *Genes Dev.*, 15:188-200 (2001); Bernstein, *et al.*, *Nature*, 409:363-6 (2001); Hammond, *et al.*, *Nature*, 404:293-6 (2000); Nykanen, *et al.*, *Cell*, 107:309-21 (2001); Martinez, *et al.*, *Cell*, 110:563-74 (2002)). The effect of iRNA or siRNA or their use is not limited to any type of mechanism.

In one embodiment, a siRNA triggers the specific degradation of homologous *NAMPT* RNA molecules, such as *NAMPT* mRNAs, within the region of sequence identity between both the siRNA and the target *NAMPT* RNA.


Sequence specific gene silencing can be achieved in mammalian cells using synthetic, short double-stranded RNAs that mimic the siRNAs produced by the enzyme dicer (Elbashir, *et al.*, *Nature*, 411:494-498 (2001)) (Ui-Tei, *et al.*, *FEBS Lett*, 479:79-82 (2000)).

siRNA can be chemically or *in vitro*-synthesized or can be the result of short double-stranded hairpin-like RNAs (shRNAs) that are processed into siRNAs inside the cell. For example, WO 02/44321 discloses siRNAs capable of sequence-specific degradation of target mRNAs when base-paired

with 3' overhanging ends, herein incorporated by reference for the method of making these siRNAs. Synthetic siRNAs are generally designed using algorithms and a conventional DNA/RNA synthesizer. Suppliers include Ambion (Austin, Texas), ChemGenes (Ashland, Massachusetts), Dharmacon (Lafayette, Colorado), Glen Research (Sterling, Virginia), MWB Biotech (Esbersberg, Germany), Proligo (Boulder, Colorado), and Qiagen (Vento, The Netherlands). siRNA can also be synthesized *in vitro* using kits such as Ambion's SILENCER® siRNA Construction Kit. In some embodiments, the composition includes a vector expressing the functional nucleic acid. The production of siRNA from a vector is more commonly done through the transcription of a short hairpin RNase (shRNAs). Kits for the production of vectors including shRNA are available, such as, for example, Imgenex's GENESUPPRESSOR™ Construction Kits and Invitrogen's BLOCK-IT™ inducible RNAi plasmid and lentivirus vectors. In some embodiments, the functional nucleic acid is siRNA, shRNA, or miRNA.

3. Small Molecule Inhibitors of NAMPT


Small molecules that specifically inhibit the transcription, translation or function of the NAMPT gene and/or gene product are described. Small molecule inhibitors of NAMPT are non-protein, non-nucleic acid molecules that have a specific function, such as binding a target molecule or reducing, preventing or otherwise moderating a specific reaction or interaction. As discussed in more detail below, The term "small molecules" generally includes a molecule of less than 10,000 Da in molecular weight. Small molecules that specifically interact with NAMPT or NAMPT receptors can act as effectors, inhibitors, modulators, and stimulators of a specific activity possessed by a target molecule, or the small molecules can possess a *de novo* activity independent of any other molecules. Preferred small molecule inhibitors of NAMPT have excellent dose-dependent enzyme inhibitory properties. Exemplary small molecule inhibitors of NAMPT include the NAMPT enzymatic inhibitors FK-866, and FK-866 analogues MS-1-82, Rari049, and Alpii135 (see **Figures 11A-11B**).

a. FK-866**FORMULA I: FK-866**


FK-866 ((E)-N-[4-(1-Benzoylpiperidin-4-yl)butyl]-3-pyridin-3-ylprop-2-enamide) is a potent, selective, non-competitive NAMPT inhibitor, which inhibits NAMPT enzymatic activity. FK-866 (formula C₂₄H₂₉N₃O₂; CAS Number 658084-64-1) is available from multiple commercial sources (*e.g.*, Abcam catalog No. ab142148).

b. Analogs of FK-866


To generate functional analogs of the NAMPT inhibitor FK-866, the FK-866 structure was divided into three regions and varied by replacing with N-heterocycles to generate FK866 analogs. Preliminary studies in MCT-PH show that Rari049 has promise as a preventive therapy reducing both right ventricular systolic pressure (RVSP), and hyper-trophy-ratio of RV and LV plus septal-S weight (RVH-RV).



FORMULA II: MS-1-82



FORMULA III: RARI-049



FORMULA IV: ALP-135

C. Excipients, Delivery Vehicles and Devices

NAMPT inhibitors can be administered with or without the aid of a delivery vehicle. Appropriate delivery vehicles for the inhibitors are known in the art and can be selected to suit the particular inhibitor. In a preferred embodiment, the inhibitor is delivered by intravenous injection or orally. Typical carriers are saline, phosphate buffered saline, and other injectable carriers.

The NAMPT inhibitors can be formulated into pharmaceutical compositions including one or more pharmaceutically acceptable carriers.

The formulation may also be in the form of a suspension or emulsion, and optionally include pharmaceutically acceptable diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers. Such compositions include the diluents sterile water, buffered saline of various buffer content (*e.g.*, Tris-HCl, acetate, phosphate), pH and ionic strength and optionally additives such as detergents and solubilizing agents (*e.g.*, TWEEN® 20, TWEEN® 80 also referred to as polysorbate 20 or 80), anti-oxidants (*e.g.*, ascorbic acid, sodium metabisulfite), and preservatives (*e.g.*, Thimersol, benzyl alcohol). Examples of non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate. The formulations may be lyophilized and redissolved/resuspended immediately before use. The formulation may be sterilized by, for example, filtration through a bacteria retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions.

The antibodies, proteins having the binding properties of antibodies, nucleic acids, or small molecules are administered to a subject in an amount effective to treat diseases and disorders in which NAMPT activity is detrimental to the subject. The antibodies are administered with or without one or more additional therapeutic agents. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also described.

III. Methods of Use

Methods of using the NAMPT inhibitors include systemically administering to a subject an effective amount of a composition including one or more NAMPT inhibitors to prevent, reduce, or inhibit the expression or function of NAMPT in the subject.

Methods for the repeated dosing regimens for using antibodies specific for NAMPT to treat PF are provided. Daily, weekly, bi-weekly and monthly dosing regimens are described. In a preferred embodiment, antibodies, F(Ab)s or F(Ab)₂'s are administered via infusion and dosing is repeated on a monthly basis. Monthly dosing has many advantages over weekly dosing including, but not limited to, a lower number of total injections, decreased number of injection site reactions (*e.g.*, local pain and swelling), increased patient compliance (*i.e.*, due to less frequent injections), and less cost to the patient as well as the health care provider.

The methods include utilizing a combination therapy wherein human antibodies are administered to a subject with another therapeutic agent, such as one or more additional antibodies that bind other targets (*e.g.*, antibodies that bind NAMPT, one or more receptors of NAMPT), one or more cytokines, soluble NAMPT receptor (*e.g.*, soluble TLR-4) and/or one or more chemical agents that inhibit NAMPT production or activity (such as small molecule inhibitors of NAMPT), or another vasoactive drug.

A. Methods of Treatment for Pulmonary Fibrosis

NAMPT inhibition has therapeutic effects in pulmonary fibrosis by reducing lung inflammation, reducing myofibroblast transition and preventing excessive fibrin deposition. In some embodiments, methods of treating disorders in which NAMPT activity is detrimental include parenteral administration of human antibodies, preferably recombinant human monoclonal antibodies, or antigen binding fragments thereof, that specifically bind to human NAMPT, or one or more specific receptors of NAMPT.

In preferred embodiments, one or more NAMPT inhibitors are effective to reduce, inhibit, or delay one or more symptoms of a disease,

disorder or condition associated with the thickening and rigidifying of blood vessels in a human patient.

Methods of using NAMPT inhibitors include, but not limited to, methods designed to inhibit or block transcription, translation, or function of the NAMPT enzyme can be used to modulate cellular functions and prevent, reduce or reverse undesirable myofibroblast accumulation. Inhibition of NAMPT can be used as a diagnostic, prophylactic or therapeutic mechanism, for example, by systemic delivery of one or more inhibitors of NAMPT or inhibitors of NAMPT ligands. Methods of treatment and prevention of diseases and disorders using the disclosed NAMPT inhibitors optionally including a delivery vehicle are discussed in more detail below.

1. Pulmonary Fibrosis (PF)

Methods of using NAMPT inhibitors for treating PH and are provided. Progressive fibrosis is a hallmark of aging in various organ systems, including the liver, kidney, pancreas and lung. IPF, the most fatal and progressive fibrotic lung disease, disproportionately affects the elderly population and is now widely regarded as a disease of aging. The incidence and prevalence of IPF increase with age; two-thirds of IPF patients are older than 60 years at the time of presentation with a mean age of 66 years at the time of diagnosis. Further, the survival rate for IPF patients markedly decreases with age.

Idiopathic Pulmonary fibrosis (IPF) is a specific subgroup of pulmonary fibrosis. IPF is a lung disease that results in scarring (fibrosis) of the lungs for an unknown reason. Over time, the scarring gets worse and it becomes hard to take in a deep breath and the lungs cannot take in enough oxygen. IPF is a form of interstitial lung disease, primarily involving the interstitium (the tissue and space around the air sacs of the lungs), and not directly affecting the airways or blood vessels. The cause of idiopathic pulmonary fibrosis is not completely understood.

Recent studies of familial and sporadic cases of IPF have been associated with telomere shortening further supporting the concept that IPF may represent an age-related degenerative disease process. The cause(s) for

the shortened telomeres in IPF patients without mutations in telomerase is currently unknown; however, oxidative stress represents one potential mechanism. Aging and fibrotic disease are both associated with cumulative oxidant burden, and lung tissue from IPF patients demonstrate “signatures” of chronic oxidative damage. The lungs are particularly prone to insult and injury by oxygen free radicals given their direct exposure to the environment and inspired air. It has been suggested that core pathways that mediate fibrosis in multiple organ systems may serve as better targets for anti-fibrotic drug development.

Common risk factors for IPF include genetic background, with up to 20% of people with IPF having another family member with an interstitial lung disease. Where more than one additional family member has IPF, the disease is termed “familial pulmonary fibrosis”.

Cigarette smoking is another factor, with approximately 75% of people with IPF being current or previous cigarette smokers. Acid reflux (gastroesophageal reflux disease [GERD]) is also another factor, with approximately 75% of people with IPF having symptoms of acid reflux (heartburn). Male sex is another risk factor, with approximately 75% of patients with IPF being male. Age is also important, with almost all patients with IPF are over the age of 50 years.

A major limitation in the field is the lack of reliable animal models that predict the efficacy of therapeutic agents in subsequent clinical trials. A commonly used model is bleomycin-induced lung injury. However, despite the preclinical efficacy of a large number of therapeutic agents using this animal model, clinical translation has been poor; thus, the use of this animal model for preclinical evaluation of candidate drugs has been questioned. A significant limitation of this model is the resolving nature of fibrosis, as bleomycin-induced lung injury results in a limited fibrotic response which resolves 4-6 weeks post-injury.

The described compositions and devices can be administered to a subject to reduce or inhibit smooth muscle cell proliferation, migration, and a combination thereof in an amount effective to reduce or myofibroblast

accumulation and thereby treat or prevent PF and other vascular disorders in the subject. In some embodiments, the patency of vessels that have been thickened and rigidified by myofibroblast accumulation can be increased using a composition containing a NAMPT inhibitor. Therefore, methods for administering a composition containing a NAMPT inhibitor to the subject prior to or after a vascular injury, surgery or trauma to prevent, reduce or reverse vascular changes due to myofibroblast accumulation in a subject in need thereof are provided.

i. Symptoms of IPF

Clinical signs of IPF indicative of a need for treatment include any one or more of dyspnea (*i.e.*, breathlessness, shortness of breath), usually during exercise, chronic cough, chest pain or tightness, unexplained weight loss, loss of appetite, fatigue, and clubbing of the digits (*i.e.*, change of finger shape).

About 85% of people with IPF have a chronic cough that has lasts longer than 8 weeks. This is often a dry cough, but some people may also cough up sputum or phlegm. Breathlessness can affect day-to-day activities such as showering, climbing stairs, getting dressed and eating. As scarring in the lungs gets worse, breathlessness may prevent all activities.

Methods for identifying a subject having IPF are known in the art, Exemplary clinical diagnostic techniques include pulmonary function test (PFT; or breathing test) to measure how much air can be inhaled/exhaled blow in and out of your lungs and capacity for lungs to absorb oxygen; six-minute walk test to determine physical fitness, as well as the amount of oxygen in the blood at rest and with physical activity; chest x-ray: Chest X to screen for interstitial lung disease and to monitor progression; blood tests for serological identity of other causes of interstitial lung disease; computed tomography (CT scan) to determine extent of scarring in the lungs; bronchoscopy to identify the presence of infection or to suggest other subtypes of interstitial lung disease; and surgical lung biopsy.

Signs of the improvement in PF, for example, in response to treatment with one or more inhibitors of NAMPT, include an improvement

in any one or more of the above symptoms.

Criteria constituting treatment failure in PF include any worsening / no change of the above symptoms, side effects such as issues with toxicity/tolerability/drug-drug interactions with drugs patient already taking, infections due to administration issues, worsening or no change in an observable factor such as 6 minute walk distance, and worsening or no change in cardiopulmonary test results (e.g., worsening oxygen consumption).

B Controls

The effect of a NAMPT inhibitor can be compared to a control. Suitable controls are known in the art and include, for example, untreated cells or an untreated human subject. In some embodiments, the control is untreated tissue from the subject that is treated, or from an untreated subject. Preferably the cells or tissue of the control are derived from the same tissue as the treated cells or tissue. In some embodiments, an untreated control subject suffers from the same disease or condition as the treated subject. For example, in some embodiments, one or more of the pharmacological or physiological markers or pathways affected by anti-NAMPT treatment is compared to the same pharmacological or physiological marker or pathway in untreated control cells or untreated control subjects. For example, anti-NAMPT treated subjects can be compared to subjects treated with other inhibitors of PF, such as, pirfenidone, nintedanib, corticosteroid, N-acetylcysteine, azathioprine, cyclophosphamide, or oxygen.

The subjects treated with other inhibitors of PF can have a greater incidence of post-operative PF, or a reduced reduction of tissue affected by fibrosis than do subjects treated with the NAMPT inhibitors.

C. Dosages and Effective Amounts for Treating PF

In some *in vivo* approaches, the compositions of NAMPT inhibitors are administered to a subject in a therapeutically effective amount for treatment of one or more of the signs or symptoms of PF.

The term “effective amount” or “therapeutically effective amount” means a dosage sufficient to treat, inhibit, or alleviate one or more symptoms

of the disorder being treated or to otherwise provide a desired pharmacologic and/or physiologic effect. The precise dosage will vary according to a variety of factors such as subject-dependent variables (*e.g.*, age, immune system health, *etc.*), the disease or disorder, and the treatment being effected.

For all of the disclosed compounds, as further studies are conducted, information will emerge regarding appropriate dosage levels for treatment of various conditions in various patients, and the ordinary skilled worker, considering the therapeutic context, age, and general health of the recipient, will be able to ascertain proper dosing. The selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment desired. Generally dosage levels of between 0.1 and 15 mg/kg of body weight are administered to humans per administration. Generally, for intravenous injection or infusion, dosage may be between 30 and 400 mg. Preferably, the compositions are formulated to achieve a NAMPT inhibitor serum level of between about 1 and about 1,000 μM .

Pharmaceutical compositions of NAMPT inhibitors are useful for the modulation of cellular processes that contribute to onset and progression of PF, including myofibroblast accumulation. Exemplary cellular processes associated with myofibroblast accumulation deposition resistance to apoptosis, enhanced deposition of extracellular matrix (ECM), including deposition of collagen and fibronectin. In some embodiments the compositions reduce or prevent the expression and/or function of the NAMPT protein and/or its interaction with ligands, such as Toll-like Receptor-4 (TLR4). Therefore, compositions and methods for treatment and prevention of PF include compositions and methods that prevent, reduce or otherwise disrupt the physiological interaction between TLR4 and NAMPT (NAMPT/TLR4). Typically, inhibitors of NAMPT/TLR4 are administered in an amount effective to reduce or prevent one or more of the downstream cellular processes associated with the physiological NAMPT/TLR4 interaction. Therefore, methods of reducing or preventing NAMPT/TLR4-mediated activation of NF κ B transcriptional activities to treat PF in a subject are also provided. In preferred embodiments, the amount of one or more

NAMPT inhibitors does not prevent or reduce normal, healthy vascular neotissue formation in the subject. Typically, the compositions include one or more small molecule NAMPT inhibitors, in an amount between 0.1-15 mg/kg body weight of a human.

1. Target-Specific Effects

In some embodiments, the NAMPT inhibitors are effective to prevent the biological activities of smooth muscle cells, such as proliferation and activation. In some embodiments, one or more inhibitors can be in an amount effective to increase or stimulate the process of apoptosis in a cell.

In one embodiment the one or more NAMPT inhibitors are in an amount effective to prevent or reduce fibrin deposition in a subject. In a preferred embodiment the amount of one or more NAMPT inhibitors does not prevent wound healing or the formation of normal, health vascular neotissue in a subject compared to an untreated control. In another embodiment, the one or more NAMPT inhibitors are in an amount effective to decrease the amount of myofibroblast accumulation, aberrant/excessive ECM production, and tissue damage. Typically, one or more NAMPT inhibitors are administered to a subject in an amount effective to decrease the amount of soluble extracellular NAMPT in the subject. Accordingly, one or more NAMPT inhibitors can be effective to reduce or prevent one or more biological activities that occur as a result of extracellular NAMPT, or as a result of downstream signaling events controlled by extracellular NAMPT. For example, by reducing or preventing the interaction between extracellular NAMPT and TLR4, NAMPT inhibitors can reduce or prevent TLR4-mediated induction of several signaling pathways controlling cellular activities including cellular proliferation, activation, chemotaxis and actin reorganization. Preferably the amount of one or more NAMPT inhibitors does not prevent the desirable healthy tissue remodeling that occurs as a component of healthy wound healing and tissue regeneration.

Inhibitors of NAMPT can be administered in an amount effective to reduce, prevent or otherwise or modify the amount, expression or functions of the NAMPT gene or NAMPT protein, or one or more receptors of

NAMPT. Therefore, in some embodiments, the inhibitors can be administered in an amount effective to reduce one or more of the transcription factors that regulate transcription of NAMPT, such as HIF-1 α , HIF-2 α , STAT5 and proline hydroxylase-2 (PHD2).

In the case of chronic PF, the process of myofibroblast accumulation within the lungs is unnecessary and undesirable, thus, enhancing apoptosis of myofibroblasts, and/or excessive ECM production and deposition is not detrimental. Therefore, inhibitors of NAMPT can be administered in an amount effective to reduce one or more of the molecular events that give rise to myofibroblast accumulation in a subject. For example, the inhibitors can be effective to reduce resistance of myofibroblast to apoptosis, reduce ECM production, reduce fibronectin, reduce collagen, and combinations thereof.

Inhibitors of NAMPT can be administered in an amount effective to enhance pulmonary compliance in a subject with PF. The desired effect can be achieved over a time period consistent with the stage and severity of the disease. For example, any one or more of the effects can be observed in a subject following administration after a period of one hour, one day, one week, one month or more than one month.

2. Therapeutic Amounts

The range for a therapeutically effective amount of an inhibitor of NAMPT can vary according to one or more of the type of inhibitor, the mechanism of action, the route of administration, the type and severity of the condition to be alleviated, and physiological parameters relating to the recipient, such as age, weight, *etc.*

An exemplary, non-limiting range for a therapeutically or prophylactically effective amount of an antibody or antibody binding fragment is between about 10 mg and 200 mg, inclusive, more preferably between about 20 mg and 100 mg and most preferably about 40 mg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated.

In some embodiments, one or more antibody or antigen binding fragments thereof inhibitors of NAMPT or NAMPT ligands is administered

via intravenous infusion to a human subject diagnosed with PF, in an amount between 0.1 and 1.5 mg/kg body weight, inclusive, to treat one or more of the signs or symptoms of chronic PF. In some embodiments, one or more antibody or antigen binding fragments thereof inhibitors of NAMPT or NAMPT ligands is administered via endotracheal administration in an amount between 10mg and 400mg body weight, inclusive, to treat one or more of the signs or symptoms of chronic PF.

In some embodiments, one or more small molecule inhibitors of NAMPT are administered to a human subject diagnosed with PF via oral or via intravenous infusion in an amount between 0.1 and 3mg/kg body weight, inclusive, for example, 10 mg/kg, 100 mg/kg, or 1 mg/kg body weight. The one or more small molecule inhibitors of NAMPT can be administered alone, or contained within liposomes.

In some embodiments, one or more cell permeable inhibitors of signal transducer and activator of transcription (STAT5), such as nicotinoyl hydrazine, SPI, or pimozide are administered to a human subject diagnosed with PF via intravenous infusion in an amount between 1 µg/kg and 20 mg/kg recipient, most preferably between 10 µg/kg and 3.5 mg/kg recipient, inclusive. The one or more inhibitors of STAT5 can be administered alone, or contained within liposomes.

In some embodiments, one or more inhibitors of ligands of NAMPT, such as TLR4, are administered to a human subject diagnosed with PF, or at risk of PF. An exemplary agent is Lipopolysaccharide from the photosynthetic bacterium *Rhodobacter sphaeroides* (LPS-RS), which is a potent antagonist of lipopolysaccharide (LPS) from pathogenic bacteria. For example, in some embodiments, LPS-RS is administered to a subject with PF or at risk of PF in an amount between 1 mg and 400 g per day.

3. Timing of Administration and Dosage Regimens

The subject can be administered one or more doses of the composition until efficacy is observed. For small molecules, these are typically administered between one day, twice weekly, or weekly. For intravenous infusion, these are typically administered weekly, monthly or

quarterly. The timing of commencement of anti-NAMPT therapy should be determined based upon the needs of the subject. In some embodiments, therapy using inhibitors of NAMPT can be discontinued once physiological signs of myofibroblast accumulation, or symptoms or PF have abated.

In some embodiments, the subject is a patient in intensive care. In the intensive care setting, the compositions including one or more NAMPT inhibitors can be administered over the course of an hour, for example, as a rescue therapy or salvage therapy. Administration may be repeated hourly, daily, weekly, or monthly, as required. In a particular embodiment, the NAMPT inhibitors are delivered via endotracheal instillation, for example, using an endotracheal tube. In other embodiments, the inhibitors are delivered to the patient via intravenous infusion over the course of one hour.

PF may be associated with an underlying autoimmune disease such as scleroderma and systemic lupus, sarcoidosis, drug toxicity such as amiodarone or nitrofurantoin or exposure to asbestos, or associated with radiation-induced lung injury. In the case of injury involving the lungs, the NAMPT inhibitors can be administered immediately, as well as subsequently throughout the healing and regeneration of the lung tissue surface.

D. Combination Therapies

The compositions including NAMPT inhibitors can be administered alone, or in combination with one or more additional active agent(s), as part of a therapeutic or prophylactic treatment regime.

The term “combination” or “combined” is used to refer to either concomitant, simultaneous, or sequential administration of two or more agents. Therefore, the combinations can be administered either concomitantly (*e.g.*, as an admixture), separately but simultaneously (*e.g.*, *via* separate intravenous lines into the same subject), or sequentially (*e.g.*, one of the compounds or agents is given first followed by the second). For example, one or more NAMPT inhibitors can be administered on the same day, or a different day than the second active agent. In some embodiments, the second active agent can be administered on the first, second, third, or fourth day, following or before one or more inhibitors of NAMPT.

In some embodiments, the additional therapeutic agent is Pirfenidone. Pirfenidone (ESBRIET®, PIRESPA®, ETUARY®) is an anti-scarring (anti-fibrotic) medication that slows the progression of IPF. Some patients taking pirfenidone have side effects, most commonly stomach upset and skin rash, particularly with exposure to sun. Pirfenidone has been approved by Health Canada for the treatment of mild to moderate IPF.

In some embodiments, the additional therapeutic agent is Nintedanib (VARGATEF®, OFEV®). Nintedanib is an anti-scarring (anti-fibrotic) medication that slows progression of IPF. Some patients taking nintedanib have side effects, most commonly including diarrhea.

In some embodiments, the additional therapeutic agent is Corticosteroid, such as Corticosteroid pills (for example, Prednisone oral pills, ORASONE®, ADASONE®) can reduce inflammation in your lungs by suppressing your immune system. Corticosteroids are only used in patients with IPF who have an acute exacerbation of their lung fibrosis, and can be harmful in patients with IPF that have scarring that is stable or slowly worsening.

In some embodiments, the additional therapeutic agent is N-Acetylcysteine (NAC; oral or aerosolized; MUCOMYST®). NAC is an antioxidant that has frequently been used in patients with IPF. A large clinical trial published in May 2014 showed that NAC does not slow progression of IPF.

In some embodiments, the additional therapeutic agent is azathioprine, cyclophosphamide, and others.

In some embodiments, the additional therapeutic agent is oxygen. Some people who have pulmonary hypertension eventually require continuous oxygen therapy.

Additional classes of drugs that can be combined with one or more inhibitors of NAMPT, and/or inhibitors of NAMPT ligands include anti-neointima agents, chemotherapeutic agents, antibiotics, antivirals, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, immune-suppressants, cytokines, chemokines and/or growth factors,

anti-proliferatives or anti-migration agents designed for treating or preventing PF, agents which affect migration and extracellular matrix production, agents which affect platelet deposition or formation of thrombus, and agents that promote vascular healing and re-endothelialization.

Exemplary antiproliferative agents include, but are not limited to, Paclitaxel (Taxol), QP-2 Vincristin, Methotrexat, Angiopeptin, Mitomycin, BCP 678, Antisense c-myc, ABT 578, Actinomycin-D, RestenASE, 1 - Chlor-deoxyadenosin, PCNA Ribozym, and Celecoxib.

Exemplary agents modulating cell replication/proliferation include targets of rapamycin (TOR) inhibitors (including sirolimus, everolimus and ABT-578), paclitaxel and antineoplastic agents, including alkylating agents (*e.g.*, cyclophosphamide, mechlorethamine, chlorambucil, melphalan, carmustine, lomustine, ifosfamide, procarbazine, dacarbazine, temozolomide, altretamine, cisplatin, carboplatin and oxaliplatin), antitumor antibiotics (*e.g.*, bleomycin, actinomycin D, mithramycin, mitomycin C, etoposide, teniposide, amsacrine, topotecan, irinotecan, doxorubicin, daunorubicin, idarubicin, epirubicin, mitoxantrone and mitoxantrone), antimetabolites (*e.g.*, deoxycoformycin, 6-mercaptopurine, 6-thioguanine, azathioprine, 2-chlorodeoxyadenosine, hydroxyurea, methotrexate, 5-fluorouracil, capecitabine, cytosine arabinoside, azacytidine, gemcitabine, fludarabine phosphate and aspariginase), antimitotic agents (*e.g.*, vincristine, vinblastine, vinorelbine, docetaxel, estramustine) and molecularly targeted agents (*e.g.*, imatinib, tretinoin, bexarotene, bevacizumab, gemtuzumab ogomicin and denileukin diftitox).

The additional therapeutic agents can be administered locally or systemically to the subject, or coated or incorporated onto, or into a device or graft. The additional therapeutic reagents can be administered by the same, or by different routes and by different means. For example, one or more NAMPT inhibitors can be delivered via infusion with one or more of paclitaxel, taxotere and other taxoid compounds, methotrexate, anthracyclines such as doxorubicin, everolimus, serolimus, rapamycin or rapamycin derivatives delivered by different means.

E. Methods for Diagnostic and Prophylactic Treatment

Given their ability to bind to NAMPT, in some embodiments, inhibitors of NAMPT are useful to detect NAMPT (*e.g.*, in a biological sample, such as blood, serum or plasma), using a conventional immunoassay, such as an enzyme linked immunosorbent assays (ELISA), an radioimmunoassay (RIA) or tissue immunohistochemistry. Therefore, methods for detecting and/or quantitating the amount of NAMPT in a biological sample are provided. The methods include contacting a biological sample with one or more inhibitors of NAMPT and detecting either the inhibitor bound to NAMPT, or the unbound inhibitor, to detect and/or quantitate the NAMPT in the biological sample. In some embodiments, the NAMPT inhibitor is an antibody or fragment thereof. For example, the anti-NAMPT antibody is directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Alternative to labeling the inhibitor, NAMPT can be assayed in biological fluids by a competition immunoassay, for example, utilizing NAMPT standards labeled with a detectable substance and an unlabeled anti-NAMPT antibody. In this assay, the biological sample, the labeled NAMPT standards and the anti-NAMPT antibody are combined and the amount of labeled NAMPT standard bound to the unlabeled antibody is determined. The amount of NAMPT in the biological sample is inversely proportional to the amount of labeled NAMPT standard bound to the anti-NAMPT antibody.

Therefore, in some embodiments, the methods include the step of identifying a subject in need of anti-NAMPT treatment, for example, a subject at risk of a disease or disorder associated with detrimental NAMPT activity. An exemplary subject is a human at risk of PF. The methods can include the step of assaying a biological fluid from the subject to determine the presence and/or quantity of NAMPT present in the sample, as compared to a normalized standard or control sample. An exemplary control sample

includes a sample of equivalent biological fluid taken from a healthy individual.

The present invention will be further understood by reference to the following non-limiting examples.

Examples

Example 1: IPF lung myofibroblasts demonstrate senescence & apoptosis-resistance.

Materials and Methods

Reagents: Porcine platelet-derived TGF- β 1 from R&D Systems (Minneapolis, MN). Staurosporine from LC Laboratories (Woburn, MA). Antibodies to: actin (clone AC-15) and α -tubulin (clone B-5-1-2) from Sigma (St. Louis, MO); α -SMA (clone ASM-1) from American Research Products (Belmont, MA); cleaved caspase 3, cleaved PARP, and Bcl-2 from Cell Signaling (Boston, MA); Nox4 and Ki67 from Novus Biologicals (Littleton, CO); and p21, Col1A1, and lamin A/C from Santa Cruz Biotechnology (Dallas, TX). Antibodies to p16INK4a were from Santa Cruz Biotechnology and BD Biosciences (San Jose, CA). Antibodies to GAPDH were from Abcam and Cell Signaling. All other reagents were purchased from Sigma (St. Louis, MO), unless otherwise specified.

Lung histology and immunohistochemical staining: Paraffin embedded tissue sections were processed for lung histology and immunohistochemical staining.

Immunofluorescence labeling: Tissue sections were permeabilized with 1% Triton-X100 in PBS, blocked with 1% BSA in PBS, and incubated with primary antibodies in PBS at room temperature for 1 h. Tissue sections were then washed with PBS followed by incubation with conjugated secondary antibodies in PBS for 1 h. Sections were then washed with PBS and nuclear staining mounting media containing DAPI was used. Slides were visualized with a fluorescent microscope and images were obtained.

TUNEL staining: Apoptotic cells in tissue slices were revealed using the In Situ Cell Death Detection Kit (Roche, Mannheim, Germany) according to kit instructions. Slices were first incubated with anti- α SMA

overnight at 4°C. After the TUNEL protocol, slides were mounted in DAPI-containing media (Vector Labs) and cells were visualized on a Zeiss fluorescent microscope. TUNEL-positive cells were counted per field in 15-20 fields and normalized to total cells from the DAPI stain.

Human lung tissue and fibroblasts were isolated from the lungs of patients with a confirmed diagnosis of IPF as previously described (18), under an approved protocol by the Institutional Review Board. Fibroblasts were isolated and evaluated for apoptosis, senescence, and ROS levels by immunofluorescence, immunohistochemistry, and/or biochemical assays.

Senescence Assays. We used a high-sensitivity substrate (fluorescein di-β-D-galactosidase) for quantitative assessment of cellular senescence (MarkerGene Technologies), according to manufacturer instructions. Cell number was normalized by DAPI (Fluorescent Cell Count Normalization Kit; MarkerGene Technologies). We also used a Senescence Detection Kit designed to histochemically detect SA-β-GAL activity in cultured cells (Abcam).

Results

Human IPF myofibroblast demonstrate senescence and apoptosis-resistance. The senescence marker, p16, was expressed in the fibroblast foci (FF), a key pathologic hallmark of IPF lung. Cells expressing Ki67, a marker of cell proliferation, were largely absent within the FF, and were primarily detected in cells at the periphery of the foci. High levels of apoptosis are detected in epithelial cells lining alveolar spaces, with little evidence of apoptosis in subepithelial αSMA-positive myofibroblasts within these foci manifest by TUNEL and immunofluorescence indicating the presence of a predominantly non-proliferative, senescent, and anti-apoptotic phenotype within FF of human IPF lungs.

Example 2: Aged mice show impaired resolution of fibrosis and accumulation of senescent myofibroblasts.

Materials and Methods

Materials and methods are described above.

Detection of H₂O₂. Extracellular H₂O₂ release was assayed from cultured cells. Cell number was normalized by DAPI (Fluorescent Cell Count Normalization Kit; MarkerGene Technologies).

Results

Figure 1 shows that aged mice demonstrate lack of resolution to bleomycin-induced lung injury compared to young mice. Aged mice exhibited myofibroblast persistence in the fibrotic regions of the lung at 2m post-injury, as determined by immune-histochemical (IHC) staining for aSMA, as compared to young mice with resolving fibrosis. **Figure 2** shows that fibroblasts isolated from young and aged mice demonstrate p16 induction in response to injury that is transient in young mice, while sustained in aged mice with persistent fibrosis. Fibroblasts isolated from injured lungs of aged mice demonstrate higher levels of senescence-associated β -galactosidase (β gal) activity, a marker of senescence, as compared to young cohorts by cellular staining for β gal. These results demonstrate that non-resolving fibrosis in aged mice is associated with persistence of senescent myofibroblasts.

Figure 3 shows that ROS generation in fibroblasts from young and aged mice at the corresponding time points (control, 3w, 2m) evaluated.

Example 3: Accumulated senescent myofibroblasts from aged mice show resistance to apoptosis.

Materials and Methods

Materials and methods are described above.

Results

Consistent with human IPF data, **Figure 4A and 4B** show that lung tissue sections from aged mice post-lung injury show lower levels of apoptosis (TUNEL + cells) in fibrotic regions in comparison to young mice. Fibroblast cells isolated from aged mice demonstrate apoptosis resistance with fewer apoptotic cells with resistance to the apoptosis-inducing agent, staurosporine (**Fig.4A**). Consistent with the acquisition of an anti-apoptotic phenotype, lungs from aged mice demonstrate elevated levels of Bcl-2 (**Fig. 4B**).

Taken together, these results demonstrate that non-resolving fibrosis in aging is associated with acquisition of a senescent and apoptosis-resistant myofibroblast phenotype.

Example 4: NAMPT protein is increased in human IPF tissues.

Materials and Methods

Materials and methods are described above.

Western immunoblotting: Cell lysates were prepared in RIPA buffer, subjected to SDS-PAGE under reducing conditions and western immunoblotting performed. Cytosolic and nuclear lysates were prepared using the Pierce Ne-Per kit or the Epigentek EpiQuik Nuclear Extraction kit according to manufacturer's recommendations.

Lysates were quantitated using a Micro BCA Protein assay kit (Pierce) or the Dc Protein assay kit (Bio Rad) according to instructions.

Results

FNAMPT protein is increased in human IPF tissues. NAMPT is specifically expressed in fibroblasts within fibrotic regions of IPF lung tissue via IHC staining for NAMPT.

Example 5: NAMPT heterozygous mice (Namt^{+/-}) are protected in an aged mouse model of pulmonary fibrosis.

Materials and Methods

Were as described in Example 4.

Results

Figure 5 shows heterozygous NAMPT mice Namt^{+/-} are protected from bleomycin-induced lung injury and lung fibrosis reflected by soluble collagen in whole lungs (compared to WT mice 3w post-injury). Further, in response to injury, Namt^{+/-} mice demonstrated increased survival compared to WT mice (80%, n = 8/10 vs. 50%, n = 5/10). These studies demonstrate proof-of-concept that *in vivo* targeting of Nampt leads to protection from lung fibrosis.

Example 6: NAMPT remains persistently expressed in the lungs of aged mice with non-resolving fibrosis.

Materials and Methods

Materials and methods were as described above.

Caspase Activity Assay. Cells were lysed using caspase lysis buffer and analyzed for activated caspase 3 using the BioVision Caspase 3 Fluorometric Assay Kit according to the manufacturer's instructions (BioVision, Inc, Milpitas CA).

Cell culture: Human fetal lung fibroblasts (IMR-90 cells) at low (11) and high (39) population doubling (PD) were purchased from Coriell Cell Repositories (Camden, NJ). Primary fibroblasts were isolated from the lungs of young and aged C57BL/6 mice. All cells were cultured in DMEM (Life Technologies, Inc.) supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT), 100 U/ml penicillin, 100 µg/ml streptomycin, and 1.25 µg/ml amphotericin B, and at 37°C in 5% CO₂, 95% air.

Real-time PCR: Total RNA was isolated from cells using the RNeasy® Mini Kit (Qiagen) and reverse transcribed using iScript Reverse Transcription SuperMix for RT-qPCR (Bio Rad) as per manufacturers' protocols. Real-time PCR reactions for each cDNA sample were performed in duplicate using SYBR® Select Master Mix (Applied Biosystems) and gene specific primer pairs for HO-1, NQO-1, GCLC, and beta-actin (Table S1, primer sequences). Reactions were carried out for 40 cycles (95°C for 15 sec, 60°C for 1 min) in a StepOnePlus Real Time PCR System (Applied Biosystems, Foster City, CA). Real-time PCR data for each target gene were normalized to endogenous α -actin and compared using the $2^{-\Delta\Delta C_t}$ method.

Results

iNampt is aberrantly regulated in aging mice and humans with IPF. iNampt is upregulated in representative fibroblasts from senescent and IPF lung fibroblasts (**Fig. 8A**). iNampt mRNA levels in fibroblasts isolated from advanced vs. early stage IPF patients show increasing *NAMPT* expression with increasing severity (**Fig. 6**).

Figure 7 shows persistent gene expression of *Nampt* (RT-PCR) is associated with non-resolving fibrosis in aging mice evaluated in lung tissue 2m post-injury injury compared to resolving fibrosis in young mice. The 2m post-injury time point represents a point where fibrosis is actively resolving in young mice, whereas aged mice are not.

Example 7: NAMPT mediates fibrotic gene responses to lung injury.

Materials and Methods

Materials and methods are described above.

Results

Figure 8A shows that eNampt increases gene expression of pathways related to fibrosis. Mice were injected intratracheally with 60µg of recombinant Nampt and lung tissue was harvested 4.5h post-administration. RNA was extracted from the lungs and 3 microarray analysis was performed (Affymetrix Mouse430_2). 630 pathways for altered gene expression were assessed; a significant enrichment in several pathways associated with lung fibrosis was identified. Importantly, in response to systemic eNampt. "Lung fibrosis" was among the most significantly altered pathways, 10th most altered out of 640 pathways assessed. **Fig 8B** is a horizontal bar graph showing genome-wide transcriptomic profiling of NAMPT silenced-lung endothelial cells and pathway analysis identifying differentially-regulated pathways. These results support a role for eNampt in mediating fibrotic responses to lung injury.

Example 8: eNampt promotes pro-fibrotic myofibroblast phenotypes.

Materials and Methods

Materials and methods were as described above.

Results

eNampt mediates pro-fibrotic myofibroblast phenotypes. Fibroblasts were dose-dependently treated with exogenous eNampt resulting in increased expression of α SMA, Nox4, iNampt, and GAPDH by western blotting. These results show that eNampt mediates fibroblast-to-myofibroblast differentiation. eNampt led to the induction of oxidant signaling, as

demonstrated by dose-dependent increases in Nox4 expression and ROS generation (**Fig. 9A**), and fibroblast senescence (**Fig. 9B**).

These studies demonstrate a role for Nampt in mediating pro-fibrotic lung myofibroblast phenotypes.

Example 9: eNampt-mediated pro-fibrotic effects require TLR4-dependent Nox4 signaling.

Materials and Methods

Materials and methods are described above.

Results

Pro-fibrotic effect of eNampt requires TLR4 signaling. eNampt is known to mediate innate immunity and transduce pro-survival signals via its known receptor, TLR4. Lung fibroblasts treated with or without a TLR4 antagonist, a competitive inhibitor of TLR4 (RS-LPS, Invitrogen), followed by treatment with/without exogenous eNampt (50 ng/ml, 48h) showed that TLR4 blockade prevented eNampt-TLR4 mediated myofibroblast differentiation, inhibited Nox4 induction as determined by Western blot, and led to decreased ROS generation (**Fig. 10**) in a dose-dependent manner.

Example 10: iNampt confers resistance to apoptosis in mice and IPF lung myofibroblasts.

Materials and Methods

Materials and methods are described above.

Results

Nampt contributes to mouse and human IPF fibroblasts resistance to apoptosis. Staurosporine (300nM, 8h)-induced expression of apoptotic markers, cleaved caspase 3 and PARP (**Fig 11A**) was increased in lung fibroblasts isolated from Nampt^{+/-} compared with WT mice.

Example 11: Pharmacologic inhibition of NAMPT enzymatic activity in IPF myofibroblasts restored susceptibility to apoptosis.

Materials and Methods

Materials and methods are described above.

Results

Figure 11B demonstrates that iNampt enzymatic activity is required for iNAMPT-mediated resistance to staurosporine-induced apoptosis in lung myofibroblasts (which express high levels of iNampt) as IPF fibroblasts pre-treated with FK-866, showed restored apoptosis.

Figures 12A-D show chemical structure of the NAMPT inhibitor, FK-866 (**Fig 12A**) which is divided into three regions (**Fig 12B**) and varied by replacing with N-heterocycles to generate novel FK866 analogs: MS-1-82(**Fig 12C**), Rari049(**Fig 12D**), Alpii135(**Fig 12E**); **Fig 13** is a bar graph showing normalized NAMPT activity in the presence of FK866 and FK analogues MS-1-82, Rari049, Alpii135 at 0.1, 1, and 10 μ M concentrations;

Figure 14 is a bar graph showing the role of Nampt enzymatic activity in H₂O₂-induced apoptosis defined by the TUNEL assay. The NAMPT enzymatic inhibitor, FK-866, blocks H₂O₂-induced apoptosis

Example 12: Fibrotic stimuli induce NAMPT promoter activity.

Materials and Methods

Materials and methods are described above.

Results

Figure 15 is a bar graph showing increased lung endothelial cell NAMPT promoter activity in response to IPF-relevant stimuli. Human lung EC, transfected with a NAMPT luciferase promoter in response to VEGF (100 ng/ml) or TGF β 1 (2 ng/ml) after exposure for 4 hr and 24 hr show increased luciferase activity.

Example 13: Anti-NAMPT Fabs potently neutralize rhNAMPT-induced NFkB phosphorylation.

Materials and Methods

Materials and methods are described above.

Results

Anti-NAMPT Fabs potently neutralize rhNAMPT-induced NFkB phosphorylation. Human lung endothelial cells (ECs) were treated with rhNAMPT alone (1 μ g/ml, 1 hr) or rhNAMPT-antibody mixture, then lysed and probed for phospho-NFkB and total NFkB via Western blot. Two

human, phage-derived Fabs, 2K and 3K, (200 ug/ml) neutralize rhNAMPT-induced NFkB phosphorylation at a greater level than the prototypic NAMPT polyclonal pAb.

We claim:

1. A composition to treat Pulmonary Fibrosis (PF) in a subject in need thereof comprising one or more inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), or one or more inhibitors of a NAMPT receptor, or combinations thereof, and, optionally, a pharmaceutically acceptable excipient for administration into the body.

2. The composition of claim 1 in a dosage formulation delivering one or more inhibitors of NAMPT, or one or more inhibitors of a NAMPT receptor, or combinations thereof, in an amount between 0.1 and 15 mg/kg body weight of a human.

3. The composition of claim 1 in a dosage effective to reduce or prevent myofibroblast accumulation in a patient with PF relative to an untreated control patient.

4. The composition of claim 1 in a dosage effective to reduce or prevent PF-induced dyspnea in a patient with PF relative to an untreated control patient.

5. The composition of claim 1 wherein one or more inhibitors of NAMPT, or inhibitors of a NAMPT receptor, or combinations thereof, are antibodies, antibody fragments thereof, or proteins having the binding specificity thereof.

6. The composition of claim 5, wherein the inhibitor is an F(Ab) fragment of an antibody that binds to NAMPT, or to a NAMPT receptor.

7. The composition of any one of claims 5-6, wherein the inhibitor of NAMPT is a divalent F(Ab)₂' fragment of an antibody that binds to NAMPT, or to a NAMPT receptor.

8. The composition of any one of claims 5-7, wherein the antibodies, antibody fragments, or proteins having the binding specificity of an anti-NAMPT antibody prevent or reduce interaction between NAMPT and one or more receptors of NAMPT.

9. The composition of claim 8, wherein the antibodies, antibody fragments, or proteins having the binding specificity of an anti-NAMPT antibody prevent or reduce interaction between NAMPT and TLR4.

10. The composition of any one of claims 5-9, wherein the antibody, antibody fragment, or protein having the binding specificity of an anti-NAMPT antibody binds to an epitope on the NAMPT protein comprising one or more residues selected from the group consisting of Glu445, Gly446, Lys447, Gly448, Asp449, Leu450, Glu451, Glu452, Tyr453, Gly454, His455, Asp456 and Leu457.
11. The composition of any one of claims 5-7, wherein the antibodies, antibody fragments, or proteins bind to the NAMPT molecule to prevent or reduce the homo-dimerization of NAMPT.
12. The composition of any one of claims 1-11 comprising the antibody, antibody fragment, or protein of any one of claims 5-11 in an amount for administration by infusion to a human with pulmonary fibrosis of between about 10 mg and about 400 mg, inclusive.
13. The composition of claim 12, wherein the antibody is in an amount for administration by infusion of between about 50 mg and about 200 mg, inclusive.
14. The composition of any one of claims 1-4 wherein one or more inhibitors of NAMPT, or inhibitors of TLR4, or combinations thereof, is a functional nucleic acid selected from the group consisting of an antisense molecule, siRNA, miRNA, aptamers, ribozymes, triplex forming molecules, RNAi, and external guide sequences.
15. The composition of claim 14 wherein one or more functional nucleic acids are expressed from an expression vector.
16. The composition of any one of claims 1-4 wherein one or more inhibitors of NAMPT is a small molecule.
17. The composition of claim 16 wherein the small molecule is selected from the group consisting of FK-866, MS-1-82, Rari049, and Al-pii135.
18. A method of treating pulmonary fibrosis in a patient, comprising administering to the patient in need thereof the composition of any one of claims 1-17.

19. The method of treating pulmonary fibrosis of claim 18 wherein the composition is an antibody or fragment thereof comprising administering by intravenous administration between 10 and 400 mg of the antibody or fragment thereof.

20. The method of claim 18, wherein one or more inhibitors of NAMPT, or inhibitors of TLR4, or combinations thereof are antibodies, antibody fragments, or proteins having the binding specificity of an anti-NAMPT antibody, or an anti-TLR4 antibody is administered by infusion in an amount between 1mg and 200mg.

21. The method of claim 20, wherein the infusion is carried out over the course of one hour.

22. The method of claim 20 wherein the composition is administered weekly, monthly or less frequently.

23. The method of claim 18 comprising administered one or more small molecules of claim 17 at a dosage of between about 1.0 mg/kg and about 3.0 mg/kg body weight of the recipient, inclusive.

24. The method of claim 23 comprising administering Rari049 in an amount of about 2.5 mg/kg body weight of the recipient.

25. The method of claim 18 wherein the patient is diagnosed with idiopathic pulmonary fibrosis, or familial pulmonary fibrosis.

26. The method of claim 18 wherein the patient has undergone, is undergoing, or will undergo vascular trauma, angioplasty, vascular surgery, or transplantation arteriopathy.

27. The method of claim 18, wherein the composition is administered for a time and in a dosage effective to reduce or prevent myofibroblast accumulation in a subject relative to an untreated control subject.

28. The method of claim 18 to reduce or prevent aberrant myofibroblast accumulation in a human subject comprising administering to the subject one or more inhibitors of nicotinamide phosphoribosyltransferase (NAMPT), or one or more inhibitors of a NAMPT receptor, or combinations thereof in an amount effective to reduce or inhibit the interaction between

NAMPT and a NAMPT receptor in the subject relative to an untreated control subject.

29. The method of claim 28, wherein the NAMPT receptor is Toll Like Receptor 4 (TLR4).




FIG. 1A






FIG. 2




FIG. 3




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6




FIG. 7

Pathway	Rank (out of 640 pathways)
Toll-like receptor signaling	2
TNF-alpha NF-KB signaling	3
Apoptosis	8
Lung fibrosis	10
Oxidative Stress	19

FIG. 8A




FIG.8B




FIG.9A




FIG.9B




FIG. 10




FIG. 11A




FIG. 11B

6/9




FIG. 12A




FIG. 12B

7/9




FIG. 12C




FIG. 12D




FIG. 12E




FIG. 13




FIG. 14




FIG. 15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US18/27799

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C12N 15/113, 15/115; A61K 39/395, 31/4545; A61P 11/00; C07K 16/28 (2018.01)

CPC -

C12N 15/113, 15/115, 15/1138, 15/1137; A61K 39/395, 31/4545, 38/005, 38/39533, 39/3955; A61P 11/00; C07K 16/28, 16/2896

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	WO 2012/118910 A2 (QUARK PHARMACEUTICALS, INC. et al.) 7 September 2012; paragraphs [0008]-[0009], [0017]-[0018], [0043], [0046]-[0047], [0060], [00135], [00266], [00268], [00273], [00366], [00373], [00401], [00405], [00425], [00427], [00437], [00462].	1-2, 5-6, 7/5-6, 14/1-2, 15/14/1-2 ----- 3-4, 14/3-4, 15/14/3-4
Y	WO 2017/031213 A1 (KARYOPHARM THERAPEUTICS INC.) 23 February 2017; paragraphs [0005]-[0007], [0079], [00128], [00129], [00131], [00152], [00158], [00176], [00178], [00193], [00223], [00276].	1-6, 7/5-6, 14/1, 16/1-4, 17/16/1-4
Y	WO 2014/144821 A1 (INTERMUNE, INC.) 18 September 2014; Table 1A; paragraphs [0016], [0054], [0058], [0075], [0076], [0082], [0086], [0107], [0108], [0145].	1-6, 7/5-6, 14/1, 16/1-4, 17/16/1-4
Y	TAO, L. et al. Mogroside IIIIE, a Novel Anti-Fibrotic Compound, Reduces Pulmonary Fibrosis Through Toll-Like Receptor 4 Pathways. The Journal of Pharmacology and Experimental Therapeutics. 9 March 2017, Vol. 361, pages 268-279, doi:10.1124/jpet.116.239137; abstract; page 269, second column, fourth paragraph; page 274, second column, first paragraph; page 278, second column, second paragraph.	3, 14/3, 15/14/3, 16/3, 17/16/3
Y	THE IDIOPATHIC PULMONARY FIBROSIS CLINICAL RESEARCH NETWORK. A Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis. N. Engl. J. Med.; 12 August 2010; pages 1-15, doi:10.1056/NEJMoa1002110; Tables 1, 2; abstract; page 2, sixth paragraph; page 6, fourth and sixth paragraphs; page 7, second paragraph.	4, 14/4, 15/14/4, 16/4, 17/16/4
Y	WO 2017/041114 A2 (THE CHILDREN'S MERCY HOSPITAL) 9 March 2017; paragraphs [000171], [000196]-[000197].	2, 16/2, 17/16/1-4,

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

08 June 2018 (08.06.2018)

Date of mailing of the international search report

03 JUL 2018

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US18/27799

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 8-13, 18-29
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.